L Number	Hits	Search Text	DB	Time stamp
1	7483	560/45, 560/11, 560/17, 562/460, 564/162, 564/163, 564/169, 564/170, 564/172, 562/429, 562/431, 514/570, 514/571, 514/563, 514/618, 514/619, 514/620, 514/621, 514/622, 514/532, 514/545	USPAT	2003/06/25 16:22
2	10647	obesity or arteriosclerosis	USPAT	2003/06/25 16:22
3	10259	thyroid$	USPAT	2003/06/25 16:23
4	46	(560/45, 560/11, 560/17, 562/460, 564/162, 564/163, 564/169, 564/170, 564/172, 562/429, 562/431, 514/570, 514/571, 514/563, 514/618, 514/619, 514/620, 514/621, 514/622, 514/532, 514/545) and (obesity or arteriosclerosis) and thyroid$	USPAT	2003/06/25 16:23

C:\Program Files\Stnexp\Queries\10082022bb.str



chain nodes :
13 16 17 18 19 20 29 30 33 34 35 37 38
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 39 40 41 42 43 44
chain bonds :
4-38 5-13 7-30 8-34 9-13 10-33 11-29 12-16 16-17 17-18 18-19 18-20 35-37 38-39
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 39-40 39-44 40-41
41-42 42-43 43-44
exact/norm bonds :
4-38 5-13 7-30 8-34 9-13 10-33 11-29 12-16 16-17 18-19 18-20 35-37 38-39
exact bonds :
17-18
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 39-40 39-44 40-41
41-42 42-43 43-44
isolated ring systems :
containing 7 : 39 :

G1:O,S,N,CH2,CH,CF2,SO2,NH

G2:O,S

G3:O,N

G4:C,S,N,CH,CF2,Ak

G5:H,Et,n-Pr,i-Pr,n-Bu,i-Bu,s-Bu,t-Bu,CH3

G7:H,CN,X,Cb,Ak,CH2,CH,CF2,CF3

G8:H,Ak

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:Atom 13:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS 20:CLASS 29:CLASS 30:CLASS
33:CLASS 34:CLASS 35:CLASS 37:CLASS 38:CLASS 39:Atom 40:Atom 41:Atom 42:Atom
43:Atom 44:Atom 45:CLASS

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:487389 CAPLUS
DOCUMENT NUMBER: 137:57585
TITLE: Dissociated glucocorticoid receptor antagonists for the treatment of glucocorticoid associated side-effect
INVENTOR(S): Thomson, David S.; Jennewein, Hans Michael; Pairet, Michel; Kalkbrenner, Frank; Kreideweiss, Stefan
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma Kg, Germany
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002049634	A2	20020627	WO 2001-EP14839	20011215
WO 2002049634	A3	20021114		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002019192	A5	20020701	AU 2002-19192	20011215
US 2002151588	A1	20021017	US 2001-29720	20011220

PRIORITY APPLN. INFO.: US 2000-256876P P 20001220
WO 2001-EP14839 W 20011215

AB The invention relates to the use of glucocorticoid receptor ligands selectively antagonizing the transactivation activity of the glucocorticoid receptor (GR) without affecting the transrepression activity. Compds. having this profile can be used as co-medication with conventional glucocorticoids in the treatment of inflammation and immune diseases. An advantage of this combination therapy is that metabolic side-effects of glucocorticoids are antagonized and only the anti-inflammatory or anti-immune activity of the glucocorticoids is maintained. In such a combination therapy, higher doses of the glucocorticoid can be used leading to better therapeutic efficacy.

IT 252201-98-2, EXRS 1370SE
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dissocd. glucocorticoid receptor antagonists for treatment of glucocorticoid assocd. side-effects in relation to anti-inflammatory activity)

RN 252201-98-2 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-methoxy-2-(3-methylbenzoyl)-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:428849 CAPLUS
DOCUMENT NUMBER: 137:5991
TITLE: Preparation of 4-phenoxyphenylacetic acids active at the glucocorticoid receptor III
INVENTOR(S): Gillner, Mikael; Hagberg, Lars; Koch, Eva; Nilsson, Marita; Wu, Jinchang
PATENT ASSIGNEE(S): Karo Bio Ab, Swed.
SOURCE: PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002044120	A1	20020606	WO 2001-IB2164	20011116
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002012629	A5	20020611	AU 2002-12629	20011116

PRIORITY APPLN. INFO.: GB 2000-29100 A 20001129
WO 2001-IB2164 W 20011116

OTHER SOURCE(S): MARPAT 137:5991
GI



I

AB The title compds. [I; R1 = CO2H, heteroaryl; R2, R3 = H, halo, alkyl, provided that one of R2 or R3 is other than H atom; R4 = alkyl, cycloalkyl, alkenyl, alkynyl; R5 = H, alkyl, alkenyl, alkynyl; R6, R7 = aryl, heteroaryl, heterocycloalkyl] or pharmaceutically acceptable salts that are liver selective glucocorticoid receptor antagonists, and are useful in therapy and in the regulation of metab., esp. lowering blood glucose levels, were prepd. Thus, reacting 3,5-dibromo-4-{2-[hydroxy(phenyl)methyl]-5-isopropyl-4-methoxyphenoxy}phenylacetic acid with phenol in the presence of SnCl2 in CH2Cl2 afforded I [R1 = CO2H; R2, R3 = Br; R4 = iso-Pr; R5 = Me; R6 = Ph; R7 = 4-HOC6H4]. The compds. I exhibit an affinity for the glucocorticoid receptor receptor in the range between 0.1 and 5000 nM.

IT 433686-51-2P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of 4-phenoxyphenylacetic acids active at the glucocorticoid receptor III)

RN 433686-51-2 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[(2-hydroxy-5-methoxyphenyl)(3-methylphenyl)methyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



IT 433686-19-2P 433686-20-5P 433686-21-6P
433686-22-7P 433686-23-8P 433686-24-9P
433686-25-0P 433686-26-1P 433686-27-2P
433686-28-3P 433686-29-4P 433686-30-7P
433686-31-8P 433686-32-9P 433686-33-0P
433686-34-1P 433686-35-2P 433686-36-3P
433686-37-4P 433686-38-5P 433686-39-6P
433686-40-9P 433686-41-0P 433686-42-1P
433686-43-2P 433686-44-3P 433686-45-4P
433686-46-5P 433686-47-6P 433686-48-7P
433686-49-8P 433686-50-1P 433686-52-3P
433686-53-4P 433686-54-5P 433686-55-6P
433686-56-7P 433686-57-8P 433686-58-9P
433686-59-0P 433686-60-3P 433686-61-4P
433686-62-5P 433686-63-6P 433686-64-7P
433686-65-8P 433686-67-0P 433686-69-2P
433686-70-5P 433686-71-6P 433686-72-7P
433686-73-8P 433686-74-9P 433686-75-0P
433686-76-1P 433686-77-2P 433686-78-3P
433686-79-4P 433686-80-7P 433686-81-8P
433686-82-9P 433686-83-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 4-phenoxyphenylacetic acids active at the glucocorticoid receptor III)

RN 433686-19-2 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[(4-hydroxyphenyl)phenylmethyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 433686-20-5 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[(5-fluoro-2-hydroxyphenyl)phenylmethyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 433686-21-6 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[(4-chloro-2-hydroxyphenyl)phenylmethyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 433686-22-7 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[(2-chloro-4-hydroxyphenyl)phenylmethyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[(4,5-difluoro-2-hydroxyphenyl)phenylmethyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 433686-26-1 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[(2-hydroxy-4,5-dimethylphenyl)phenylmethyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 433686-27-2 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[(2-hydroxy-5-methoxyphenyl)phenylmethyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 433686-28-3 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-(1H-indol-3-ylphenylmethyl)-4-methoxy-

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 433686-23-8 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[(5-chloro-2-hydroxyphenyl)phenylmethyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 433686-24-9 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[(3,4-difluoro-2-hydroxyphenyl)phenylmethyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 433686-25-0 CAPLUS

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)
5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 433686-29-4 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[(4-hydroxyphenyl)(3-methylphenyl)methyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 433686-30-7 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[(3-fluoro-2-hydroxyphenyl)(3-methylphenyl)methyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 433686-31-8 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[(4-fluoro-2-hydroxyphenyl)(3-methylphenyl)methyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 433686-32-9 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[(5-fluoro-2-hydroxyphenyl)(3-methylphenyl)methyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 433686-35-2 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[(5-chloro-2-hydroxyphenyl)(3-methylphenyl)methyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 433686-36-3 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[(3-bromo-2-hydroxyphenyl)(3-methylphenyl)methyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 433686-33-0 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[(3-chloro-2-hydroxyphenyl)(3-methylphenyl)methyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 433686-34-1 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[(4-chloro-2-hydroxyphenyl)(3-methylphenyl)methyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 433686-37-4 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[(4-bromo-2-hydroxyphenyl)(3-methylphenyl)methyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 433686-38-5 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[(5-bromo-2-hydroxyphenyl)(3-methylphenyl)methyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 433686-39-6 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[(2,4-dichloro-6-hydroxyphenyl)(3-methylphenyl)methyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 433686-40-9 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[(2-hydroxy-3-methylphenyl)(3-methylphenyl)methyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 433686-43-2 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[(2-hydroxy-3,6-dimethylphenyl)(3-methylphenyl)methyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 433686-44-3 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[(2-hydroxy-4,5-dimethylphenyl)(3-methylphenyl)methyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 433686-45-4 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[(2-hydroxy-4,6-dimethylphenyl)(3-

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 433686-41-0 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[(2-hydroxy-3,4-dimethylphenyl)(3-methylphenyl)methyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 433686-42-1 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[(2-hydroxy-3,5-dimethylphenyl)(3-methylphenyl)methyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 433686-46-5 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[(5-ethyl-2-hydroxyphenyl)(3-methylphenyl)methyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 433686-47-6 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[[5-(1,1-dimethylethyl)-2-hydroxyphenyl](3-methylphenyl)methyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 433686-48-7 CAPLUS

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)
CN Benzenepropanoic acid, 3-[[2-[2,6-dibromo-4-(carboxymethyl)phenoxy]-5-methoxy-4-(1-methylethyl)phenyl](3-methylphenyl)methyl]-4-hydroxy-, .alpha.-methyl ester (9CI) (CA INDEX NAME)



RN 433686-49-8 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[(2,4-dihydroxyphenyl)(3-methylphenyl)methyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 433686-50-1 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[(2-hydroxy-4-methoxyphenyl)(3-methylphenyl)methyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 433686-54-5 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[[2-hydroxy-5-(phenylmethoxy)phenyl](3-methylphenyl)methyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 433686-55-6 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[(2-hydroxy-3-methoxy-6-methylphenyl)(3-methylphenyl)methyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 433686-52-3 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[[2-hydroxy-4-(trifluoromethoxy)phenyl](3-methylphenyl)methyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 433686-53-4 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[[2-hydroxy-6-(trifluoromethoxy)phenyl](3-methylphenyl)methyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 433686-56-7 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[(2-hydroxy-3,4-dimethoxyphenyl)(3-methylphenyl)methyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 433686-57-8 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[(2-hydroxy-4,6-dimethoxyphenyl)(3-methylphenyl)methyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 433686-58-9 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[(6-hydroxy-2,3,4-trimethoxyphenyl)(3-

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)
methylphenyl)methyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 433686-59-0 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[(6-hydroxy-1,3-benzodioxol-5-yl)(3-methylphenyl)methyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)





RN 433686-60-3 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[(5-hydroxy-1,3-benzodioxol-4-yl)(3-methylphenyl)methyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 433686-63-6 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[[2-hydroxy-5-(1H-pyrrol-1-yl)phenyl](3-methylphenyl)methyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 433686-64-7 CAPLUS
CN Benzeneacetic acid, 4-[2-[(3-amino-2-hydroxy-1-naphthalenyl)(3-methylphenyl)methyl]-4-methoxy-5-(1-methylethyl)phenoxy]-3,5-dibromo- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 433686-61-4 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[(2,4-dimethoxyphenyl)(3-methylphenyl)methyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 433686-62-5 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[(4-(dimethylamino)phenyl](3-methylphenyl)methyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)
RN 433686-65-8 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[1H-indol-3-yl(3-methylphenyl)methyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 433686-67-0 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[(5-bromo-1H-indol-3-yl)(3-methylphenyl)methyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 433686-69-2 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-methoxy-5-(1-methylethyl)-2-[(1-methyl-1H-indol-3-yl)(3-methylphenyl)methyl]phenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 433686-70-5 CAPLUS
CN 1H-Indole-4-carboxylic acid, 3-[[2-[2,6-dibromo-4-(carboxymethyl)phenoxy]-5-methoxy-4-(1-methylethyl)phenyl](3-methylphenyl)methyl]-, 4-methyl ester (9CI) (CA INDEX NAME)



RN 433686-71-6 CAPLUS
CN 1H-Indole-5-carboxylic acid, 3-[[2-[2,6-dibromo-4-(carboxymethyl)phenoxy]-5-methoxy-4-(1-methylethyl)phenyl](3-methylphenyl)methyl]-, 5-methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 433686-74-9 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[(3,5-dimethylphenyl)(5-fluoro-2-hydroxyphenyl)methyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 433686-75-0 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[(4-bromo-2-hydroxyphenyl)(3-methylphenyl)methyl]-5-(1,1-dimethylethyl)-4-methoxyphenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 433686-72-7 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-methoxy-5-(1-methylethyl)-2-[(3-methylphenyl)-2-thienylmethyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 433686-73-8 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[(3,5-dimethylphenyl)(4-hydroxyphenyl)methyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 433686-76-1 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[(2-bromo-4-hydroxyphenyl)(3-methylphenyl)methyl]-5-(1,1-dimethylethyl)-4-methoxyphenoxy]- (9CI) (CA INDEX NAME)



RN 433686-77-2 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[(2-bromo-6-hydroxyphenyl)(3-methylphenyl)methyl]-5-(1,1-dimethylethyl)-4-methoxyphenoxy]- (9CI) (CA INDEX NAME)



RN 433686-78-3 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[5-(1,1-dimethylethyl)-2-[(2-hydroxy-4,6-

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)
dimethylphenyl)(3-methylphenyl)methyl]-4-methoxyphenoxy]- (9CI) (CA INDEX NAME)



RN 433686-79-4 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[5-(1,1-dimethylethyl)-2-[(2-hydroxy-3-methoxy-6-methylphenyl)(3-methylphenyl)methyl]-4-methoxyphenoxy]- (9CI) (CA INDEX NAME)



RN 433686-80-7 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[5-cyclopentyl-2-[(2-hydroxy-3-methoxy-5-methylphenyl)(3-methylphenyl)methyl]-4-methoxyphenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)
methylphenyl)methyl]-4-hydroxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



IT **348166-50-7 348166-93-8 433686-84-1**
433686-85-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of 4-phenoxyphenylacetic acids active at the glucocorticoid receptor III)
RN 348166-50-7 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[hydroxy(3-methylphenyl)methyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 348166-93-8 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[(3,5-dimethylphenyl)hydroxymethyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 433686-81-8 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-(diphenylmethyl)-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 433686-82-9 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[1H-imidazol-1-yl(3-methylphenyl)methyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 433686-83-0 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[(2,5-dihydroxyphenyl)(3-

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 433686-84-1 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[5-(1,1-dimethylethyl)-2-[hydroxy(3-methylphenyl)methyl]-4-methoxyphenoxy]- (9CI) (CA INDEX NAME)



RN 433686-85-2 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[5-cyclopentyl-2-(hydroxyphenylmethyl)-4-methoxyphenoxy]- (9CI) (CA INDEX NAME)



IT **252043-61-1P 348166-39-2P 348166-62-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of 4-phenoxyphenylacetic acids active at the glucocorticoid receptor III)
RN 252043-61-1 CAPLUS
CN Benzeneacetic acid, 4-[2-benzoyl-4-methoxy-5-(1-methylethyl)phenoxy]-3,5-

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)
dibromo-, methyl ester (9CI) (CA INDEX NAME)



RN 348166-39-2 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-(hydroxyphenylmethyl)-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 348166-62-1 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[chloro(3-methylphenyl)methyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:428637 CAPLUS
DOCUMENT NUMBER: 137:20220
TITLE: Preparation of 4-phenoxyphenylacetic acids active at the glucocorticoid receptor II
INVENTOR(S): Pelcman, Benjamin; Gustafsson, Annika; Kym, Philip R.
PATENT ASSIGNEE(S): Karo Bio AB, Swed.; Abbot Laboratories
SOURCE: PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002043648	A2	20020606	WO 2001-IB2302	20011128
WO 2002043648	C1	20020906		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002023105	A5	20020611	AU 2002-23105	20011128
PRIORITY APPLN. INFO.:			GB 2000-29102 A	20001129
			WO 2001-IB2302 W	20011128
OTHER SOURCE(S):		MARPAT 137:20220		

GI



AB The title compds. [I; X = CH2, CHYR7, CHYCOR7, CO, CS, C:NOR8; Y = O, S, NR8; R1 = CO2H, heteroaryl; R2, R3 = H, halo, alkyl, provided that one of R2 or R3 is other than hydrogen; R4 = alkyl, alkenyl, alkynyl, halo, etc.; R5 = alkyl which is substituted by A (provided that A is not halo), alkyl, alkenyl, etc.; R6 = alkyl, cycloalkyl, heterocycloalkyl, etc.; R7 = H; R8 = H, alkyl, cycloalkyl, etc.; A = halo, cycloalkyl, alkenyl, etc.] that are liver selective glucocorticoid receptor antagonists, useful in therapy

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)
and in the regulation of metab., esp. lowering blood glucose levels, were prepd. E.g., a multi-step synthesis of I [R1 = CO2H; R2, R3 = Br; R4 = iso-Pr; R5 = (CH2)2C(:CH2)Me; X = CO; R6 = 3-MeC6H4] was given. The compds. I exhibit an affinity for the glucocorticoid receptor in the range between 0.1 and 5000 nM.

IT 434327-06-7P 434327-07-8P 434327-08-9P
434327-09-0P 434327-10-3P 434327-11-4P
434327-12-5P 434327-13-6P 434327-14-7P
434327-15-8P 434327-16-9P 434327-17-0P
434327-18-1P 434327-19-2P 434327-20-5P
434327-21-6P 434327-22-7P 434327-23-8P
434327-24-9P 434327-25-0P 434327-26-1P
434327-27-2P 434327-28-3P 434327-29-4P
434327-30-7P 434327-31-8P 434327-32-9P
434327-33-0P 434327-34-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 4-phenoxyphenylacetic acids active at the glucocorticoid receptor II)

RN 434327-06-7 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-(3-methylbenzoyl)-4-[(3-methyl-3-butenyl)oxy]-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 434327-07-8 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-(3-methylbenzoyl)-5-(1-methylethyl)-4-(2-propynyloxy)phenoxy]- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 434327-08-9 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-(3-methylbenzoyl)-5-(1-methylethyl)-4-(3-pentynyloxy)phenoxy]- (9CI) (CA INDEX NAME)



RN 434327-09-0 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-(2-methoxyethoxy)-2-(3-methylbenzoyl)-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 434327-10-3 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-[2-(2-methoxyethoxy)ethoxy]-2-(3-methylbenzoyl)-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 434327-11-4 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]-2-(3-methylbenzoyl)-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

RN 434327-12-5 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-[(7-hydroxyheptyl)oxy]-2-(3-methylbenzoyl)-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 434327-16-9 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-(3-methylbenzoyl)-5-(1-methylethyl)-4-(phenylmethoxy)phenoxy]- (9CI) (CA INDEX NAME)



RN 434327-17-0 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-[(2-fluorophenyl)methoxy]-2-(3-methylbenzoyl)-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 434327-13-6 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-[2-(ethylthio)ethoxy]-2-(3-methylbenzoyl)-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 434327-14-7 CAPLUS
CN Benzeneacetic acid, 4-[2-benzoyl-4-(carboxymethoxy)-5-(1-methylethyl)phenoxy]-3,5-dibromo- (9CI) (CA INDEX NAME)



RN 434327-15-8 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-[(5-carboxypentyl)oxy]-2-(3-methylbenzoyl)-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 434327-18-1 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-[(3-fluorophenyl)methoxy]-2-(3-methylbenzoyl)-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 434327-19-2 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-[(4-fluorophenyl)methoxy]-2-(3-methylbenzoyl)-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 434327-20-5 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-(3-methylbenzoyl)-5-(1-methylethyl)-4-[(3-methylphenyl)methoxy]phenoxy]- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A



PAGE 2-A

RN 434327-23-8 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-(3-methylbenzoyl)-5-(1-methylethyl)-4-[(3-nitrophenyl)methoxy]phenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 434327-21-6 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-[[4-(1,1-dimethylethyl)phenyl]methoxy]-2-(3-methylbenzoyl]-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 434327-22-7 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-(3-methylbenzoyl)-5-(1-methylethyl)-4-[[4-(trifluoromethoxy)phenyl]methoxy]phenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 434327-24-9 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-[(4-carboxyphenyl)methoxy]-2-(3-methylbenzoyl)-5-(1-methylethyl]phenoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 2-A

RN 434327-25-0 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-[[4-(methoxycarbonyl)phenyl]methoxy]-2-(3-methylbenzoyl)-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 434327-26-1 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-[(3,5-difluorophenyl)methoxy]-2-(3-methylbenzoyl)-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 434327-27-2 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-[(5-bromo-2-methoxyphenyl)methoxy]-2-(3-methylbenzoyl)-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 434327-28-3 CAPLUS

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)
CN Benzeneacetic acid, 3,5-dibromo-4-[4-[(6-chloro-1,3-benzodioxol-5-yl)methoxy]-2-(3-methylbenzoyl)-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 434327-29-4 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-(3-methylbenzoyl)-5-(1-methylethyl)-4-(4-pyridinylmethoxy)phenoxy]- (9CI) (CA INDEX NAME)



RN 434327-30-7 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-(3-methylbenzoyl)-5-(1-methylethyl)-4-[2-(4-methyl-5-thiazolyl)ethoxy]phenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 434327-31-8 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-(3-methylbenzoyl)-5-(1-methylethyl)-4-[(3-phenyl-2-propenyl)oxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 434327-32-9 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-(3-methylbenzoyl)-5-(1-methylethyl)-4-(4-phenylbutoxy)phenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 434327-33-0 CAPLUS
CN Benzeneacetic acid,
3,5-dibromo-4-[2-(3-methylbenzoyl)-5-(1-methylethyl)-4-
[2-(1-piperidinyl)ethoxy]phenoxy]- (9CI). (CA INDEX NAME)

PAGE 1-A



L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 2-A

RN 434327-34-1 CAPLUS
CN Benzeneacetic acid,
3,5-dibromo-4-[2-(3-methylbenzoyl)-5-(1-methylethyl)-4-
[2-(4-morpholinyl)ethoxy]phenoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

IT 252043-62-2P 252201-98-2P 348167-25-9P
348167-27-1P

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of 4-phenoxyphenylacetic acids active at the glucocorticoid receptor II)
RN 252043-62-2 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-methoxy-2-(3-methylbenzoyl)-5-(1-methylethyl)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 252201-98-2 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-methoxy-2-(3-methylbenzoyl)-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 348167-25-9 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-hydroxy-2-(3-methylbenzoyl)-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)
RN 348167-27-1 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-hydroxy-2-(3-methylbenzoyl)-5-(1-methylethyl)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:489346 CAPLUS
DOCUMENT NUMBER: 135:92440
TITLE: Preparation of diphenyl ethers as liver selective glucocorticoid receptor antagonists
INVENTOR(S): Apelqvist, Theresa; Gillner, Mikael; Gustavsson, Annika; Hagberg, Lars; Koch, Eva; Lindberg, Marita; Pelcman, Benjamin; Wu, Jinchang; Kym, Philip R.
PATENT ASSIGNEE(S): Karo Bio AB, Swed.; Abbott Laboratories
SOURCE: PCT Int. Appl., 79 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001047859	A1	20010705	WO 2000-IB1927	20001206
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1265839	A1	20021218	EP 2000-993605	20001206
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003519110	T2	20030617	JP 2001-549333	20001206

PRIORITY APPLN. INFO.: GB 1999-28805 A 19991207
WO 2000-IB1927 W 20001206
OTHER SOURCE(S): MARPAT 135:92440
GI

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



I



II

AB The title compds. (I) [wherein R1 = CO2H, CONHOH, COCO2H, SO3H, P(O)(OH)(OR8), P(O)(OH)(NR9R10), or (un)substituted heteroaryl; R2 and R3 = independently H, halo, (halo)alkyl, OH, (halo)alkoxy, (halo)alkylthio, perfluoroalkyl, or perfluoroalkoxy; R4 R5, R6, and R7 = independently (un)substituted (perfluoro)alkyl, cycloalkyl, alkenyl, or alkynyl; or R4 and R5 = independently (un)substituted heterocycloalkyl or (hetero)aryl; or R4, R6, and R7 = independently halo, OR8, SR8, SOR8, SO2R8, NR9R10, NR11C(Z)R8, NR11C(Z)NR9R10, NR11SO2R11, or NR11SO2NR9R10; or R6 and R7 = independently OC(Z)R8, OC(Z)OR8, OC(Z)NR9R10, OSO2NR9R10, NR11SO2R8, etc.; R8, R9, R10, and R11 = independently H or (un)substituted (perfluoro)alkyl, cycloalkyl, alkenyl, alkynyl, heterocycloalkyl, (hetero)aryl, etc.; Y = H, OH, (halo)alkoxy, perfluoroalkoxy, acyloxy, (halo)alkylthio, perfluoroalkylthio, alkylsulfonyloxy, azido, or NR9NR10; Z = O, S, NR8, N(NR9R10), N(OR8), NSO2NR9R10, N(CN), CH(NO2), or CR9R10; or pharmaceutically acceptable salts, stereoisomers, or prodrugs thereof] were prepd. as liver selective glucocorticoid receptor antagonists for the regulation of metab., esp. lowering blood glucose levels. For example, a soln. of 3,5-dibromo-4-hydroxyphenylacetic acid Me ester and TEA in CH2Cl2 was added to a mixt. of bis(3-isopropyl-4-methoxyphenyl)iodonium tetrafluoroborate (prepn. given) and copper bronze in CH2Cl2 to give 3,5-dibromo-4-(3-isopropyl-4-methoxyphenoxy)phenylacetic acid Me ester (76%). Conversion to the ketone via a Friedel-Crafts reaction with AcCl (76%) and redn. using NaBH4 in MeOH and LiOH (91%) gave II. I exhibited affinity for the glucocorticoid receptor in the range between 0.1 and 5000 nM. Thus, I are useful for the treatment of diseases assocd. with metab. dysfunction, such as Type I and Type II diabetes, Cushing's syndrome, and inflammation (no data).

IT 348166-47-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(intermediate; prepn. of di-Ph ether liver selective glucocorticoid receptor antagonists starting from phenols and diphenyliodonium salts)

RN 348166-47-2 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[(2,4-difluorophenoxy)(2-methylphenyl)methyl]-4-methoxy-5-(1-methylethyl)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



IT 252043-61-1P 252043-62-2P 252201-98-2P
258819-65-7P 258819-74-8P 258820-02-9P
258820-03-0P 258820-17-6P 348166-42-7P
348166-45-0P 348166-46-1P 348166-49-4P
348166-52-9P 348166-54-1P 348166-56-3P
348166-65-4P 348166-92-7P 348166-94-9P
348166-95-0P 348166-99-4P 348167-00-0P
348167-03-3P 348167-04-4P 348167-10-2P
348167-11-3P 348167-14-6P 348167-15-7P
348167-20-4P 348167-21-5P 348167-22-6P
348167-25-9P 348167-27-1P 348167-28-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of di-Ph ether liver selective glucocorticoid receptor antagonists starting from phenols and diphenyliodonium salts)

RN 252043-61-1 CAPLUS
CN Benzeneacetic acid, 4-[2-benzoyl-4-methoxy-5-(1-methylethyl)phenoxy]-3,5-dibromo-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 252043-62-2 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-methoxy-2-(3-methylbenzoyl)-5-(1-methylethyl)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 252201-98-2 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-methoxy-2-(3-methylbenzoyl)-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 258819-65-7 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-(3-iodobenzoyl)-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 258819-74-8 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-(3,5-difluorobenzoyl)-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 258820-02-9 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-methoxy-2-(2-methylbenzoyl)-5-(1-methylethyl)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 258820-03-0 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-methoxy-2-(4-methylbenzoyl)-5-(1-methylethyl)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

methylphenyl)methyl]-5-(1-methylethyl)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 348166-46-1 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[chloro(2-methylphenyl)methyl]-4-methoxy-5-(1-methylethyl)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 348166-49-4 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-methoxy-5-(1-methylethyl)-2-[(2-methylphenyl)[(2-methylpropyl)amino]methyl]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 348166-52-9 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-methoxy-2-[methoxy(3-methylphenyl)methyl]-5-(1-methylethyl)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 258820-17-6 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-(3,5-difluorobenzoyl)-4-methoxy-5-(1-methylethyl)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 348166-42-7 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-methoxy-5-(1-methylethyl)-2-[[2-(methylsulfonyl)ethoxy]phenylmethyl]phenoxy]-, 2-(methylsulfonyl)ethyl ester (9CI) (CA INDEX NAME)



RN 348166-45-0 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-methoxy-2-[methoxy(2-

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 348166-54-1 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-methoxy-2-[(1-methylethoxy)(3-methylphenyl)methyl]-5-(1-methylethyl)phenoxy]-, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 348166-56-3 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[(cyclohexyloxy)(3-methylphenyl)methyl]-4-methoxy-5-(1-methylethyl)phenoxy]-, cyclohexyl ester (9CI) (CA INDEX NAME)



RN 348166-65-4 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-methoxy-5-(1-methylethyl)-2-[[(1-methylethyl)amino](3-methylphenyl)methyl]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 348166-92-7 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[3-(dimethylamino)benzoyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 348166-94-9 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-(3,5-dimethylbenzoyl)-4-methoxy-5-(1-methylethyl)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 348166-95-0 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-(3,5-dimethylbenzoyl)-4-methoxy-5-(1-

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 348167-03-3 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-(4-fluoro-3-methylbenzoyl)-4-methoxy-5-(1-methylethyl)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 348167-04-4 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-(4-fluoro-3-methylbenzoyl)-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 348167-10-2 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[5-(2-cyclopentylethyl)-4-methoxy-2-(3-methylbenzoyl)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)
methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 348166-99-4 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-(3-chloro-2-fluorobenzoyl)-4-methoxy-5-(1-methylethyl)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 348167-00-0 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-(3-chloro-2-fluorobenzoyl)-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 348167-11-3 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[5-(2-cyclopentylethyl)-4-methoxy-2-(3-methylbenzoyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 348167-14-6 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[5-iodo-4-methoxy-2-(3-methylbenzoyl)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)
RN 348167-15-7 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[5-iodo-4-methoxy-2-(3-methylbenzoyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 348167-20-4 CAPLUS
CN Benzeneacetic acid, 4-[5-(acetylamino)-4-methoxy-2-(3-methylbenzoyl)phenoxy]-3,5-dibromo-, methyl ester (9CI) (CA INDEX NAME)



RN 348167-21-5 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-methoxy-2-(3-methylbenzoyl)-5-[(3-methylbenzoyl)amino]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)
RN 348167-27-1 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-hydroxy-2-(3-methylbenzoyl)-5-(1-methylethyl)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 348167-28-2 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-(3-methylbenzoyl)-5-(1-methylethyl)-4-(2-methylpropoxy)phenoxy]- (9CI) (CA INDEX NAME)



IT 348166-43-8P 348166-51-8P 348166-59-6P
348166-62-1P 348166-82-5P 348166-93-8P
348166-98-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of di-Ph ether liver selective glucocorticoid receptor antagonists starting from phenols and diphenyliodonium salts)
RN 348166-43-8 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[hydroxy(2-methylphenyl)methyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 348167-22-6 CAPLUS
CN Benzeneacetic acid, 4-[5-(acetylamino)-4-methoxy-2-(3-methylbenzoyl)phenoxy]-3,5-dibromo- (9CI) (CA INDEX NAME)



RN 348167-25-9 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-hydroxy-2-(3-methylbenzoyl)-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 348166-51-8 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-methoxy-2-[methoxy(3-methylphenyl)methyl]-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 348166-59-6 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-methoxy-5-(1-methylethyl)-2-[(3-methylphenyl)(4-nitrophenoxy)methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 348166-62-1 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[chloro(3-methylphenyl)methyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 348166-82-5 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[hydroxy(4-methylphenyl)methyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 348166-93-8 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[(3,5-dimethylphenyl)hydroxymethyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 348166-98-3 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[(3-chloro-2-fluorophenyl)hydroxymethyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 348166-41-6 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-methoxy-5-(1-methylethyl)-2-[[2-(methylsulfonyl)ethoxy]phenylmethyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 348166-44-9 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[(2,4-difluorophenoxy)(2-methylphenyl)methyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 348166-48-3 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-methoxy-5-(1-methylethyl)-2-[(2-methylphenyl)[(2-methylpropyl)amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



IT 348166-39-2P 348166-41-6P 348166-44-9P
348166-48-3P 348166-50-7P 348166-53-0P
348166-55-2P 348166-57-4P 348166-58-5P
348166-60-9P 348166-61-0P 348166-63-2P
348166-64-3P 348166-67-6P 348166-68-7P
348166-69-8P 348166-70-1P 348166-71-2P
348166-72-3P 348166-73-4P 348166-74-5P
348166-75-6P 348166-76-7P 348166-77-8P
348166-78-9P 348166-79-0P 348166-80-3P
348166-83-6P 348166-84-7P 348166-85-8P
348166-86-9P 348166-87-0P 348166-88-1P
348166-89-2P 348166-90-5P 348166-96-1P
348166-97-2P 348167-01-1P 348167-02-2P
348167-05-5P 348167-12-4P 348167-16-8P
348167-23-7P 348167-26-0P 348167-29-3P
348167-30-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of di-Ph ether liver selective glucocorticoid receptor antagonists starting from phenols and diphenyliodonium salts)

RN 348166-39-2 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-(hydroxyphenylmethyl)-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 348166-50-7 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[hydroxy(3-methylphenyl)methyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 348166-53-0 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-methoxy-2-[(1-methylethoxy)(3-methylphenyl)methyl]-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 348166-55-2 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[(cyclohexyloxy)(3-methylphenyl)methyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 348166-57-4 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[(4-fluorophenoxy)(3-methylphenyl)methyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 348166-58-5 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-methoxy-2-[(4-methoxyphenoxy)(3-methylphenyl)methyl]-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 348166-60-9 CAPLUS
CN Benzeneacetic acid, 4-[2-[(4-aminophenoxy)(3-methylphenyl)methyl]-4-methoxy-5-(1-methylethyl)phenoxy]-3,5-dibromo- (9CI) (CA INDEX NAME)



RN 348166-61-0 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[[(4-hydroxybenzoyl)oxy](3-methylphenyl)methyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 348166-63-2 CAPLUS
CN Benzeneacetic acid, 4-[2-[amino(3-methylphenyl)methyl]-4-methoxy-5-(1-methylethyl)phenoxy]-3,5-dibromo- (9CI) (CA INDEX NAME)



RN 348166-64-3 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-methoxy-5-(1-methylethyl)-2-[[(1-methylethyl)amino](3-methylphenyl)methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 348166-67-6 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[(cyclopropylamino)(3-methylphenyl)methyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 348166-68-7 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-methoxy-5-(1-methylethyl)-2-[(3-methylphenyl)-1-pyrrolidinylmethyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 348166-69-8 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-methoxy-5-(1-methylethyl)-2-[(3-methylphenyl)-1-piperidinylmethyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 348166-70-1 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-methoxy-2-[[(2-methoxyethyl)amino](3-methylphenyl)methyl]-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 348166-71-2 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[[[2-(diethylamino)ethyl]amino](3-methylphenyl)methyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 348166-72-3 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-methoxy-5-(1-methylethyl)-2-[(3-methylphenyl)[[2-(1-piperidinyl)ethyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 348166-75-6 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[[(3-carboxyphenyl)amino](3-methylphenyl)methyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 348166-76-7 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[[(4-hydroxybenzoyl)amino](3-methylphenyl)methyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 348166-73-4 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-methoxy-5-(1-methylethyl)-2-[(3-methylphenyl)-1-piperazinylmethyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 348166-74-5 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-methoxy-2-[[[(4-methoxyphenyl)methyl]amino](3-methylphenyl)methyl]-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 348166-77-8 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-methoxy-5-(1-methylethyl)-2-[(3-methylphenyl)[[(4-methylphenyl)sulfonyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 348166-78-9 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-methoxy-5-(1-methylethyl)-2-[(3-methylphenyl)[(phenylmethyl)thio]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 348166-79-0 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[[(2-furanylmethyl)thio](3-methylphenyl)methyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 348166-80-3 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[[(carboxymethyl)thio](3-methylphenyl)methyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 348166-83-6 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-methoxy-2-[(1-methylethoxy)(4-methylphenyl)methyl]-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 348166-84-7 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[hydroxy[3-(1-

CN Benzeneacetic acid, 3,5-dibromo-4-[2-[hydroxy[3-(trifluoromethyl)phenyl]methyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI)
(CA INDEX NAME)



RN 348166-88-1 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-methoxy-2-[methoxy[3-(trifluoromethyl)phenyl]methyl]-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 348166-89-2 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[hydroxy[3-(trifluoromethoxy)phenyl]methyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 348166-90-5 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[[3-(dimethylamino)phenyl]hydroxymethyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)

methylethyl)phenyl]methyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 348166-85-8 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[(3-fluorophenyl)hydroxymethyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 348166-86-9 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[hydroxy(3-iodophenyl)methyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 348166-87-0 CAPLUS



RN 348166-96-1 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[(cyclohexyloxy)(3,5-dimethylphenyl)methyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 348166-97-2 CAPLUS
CN Benzeneacetic acid, 3,5-difluorophenyl)hydroxymethyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 348167-01-1 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[(3-chloro-2-fluorophenyl)methoxymethyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI)

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)
(CA INDEX NAME)



RN 348167-02-2 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[(4-fluoro-3-methylphenyl)hydroxymethyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 348167-05-5 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[5-(2-cyclopentylethyl)-2-[hydroxy(3-methylphenyl)methyl]-4-methoxyphenoxy]- (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 348167-26-0 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[hydroxy(3-methylphenyl)methyl]-5-(1-methylethyl)-4-(2-methylpropoxy)phenoxy]- (9CI) (CA INDEX NAME)



RN 348167-29-3 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-(2-fluoroethoxy)-2-[hydroxy(3-methylphenyl)methyl]-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 348167-30-6 CAPLUS
CN Benzenepropanoic acid, 3,5-dibromo-4-[2-[hydroxy(3-methylphenyl)methyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 348167-12-4 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[hydroxy(3-methylphenyl)methyl]-5-iodo-4-methoxyphenoxy]- (9CI) (CA INDEX NAME)



RN 348167-16-8 CAPLUS
CN Benzeneacetic acid, 4-[5-(acetylamino)-2-[hydroxy(3-methylphenyl)methyl]-4-methoxyphenoxy]-3,5-dibromo- (9CI) (CA INDEX NAME)



RN 348167-23-7 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[hydroxy(3-methylphenyl)methyl]-4-methoxy-5-[(3-methylbenzoyl)amino]phenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



IT 348166-66-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; prepn. of di-Ph ether liver selective glucocorticoid receptor antagonists starting from phenols and diphenyliodonium salts)
RN 348166-66-5 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-(chloro(3-methylphenyl)methyl]-4-methoxy-5-(1-methylethyl)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2000:117013 CAPLUS
DOCUMENT NUMBER: 132:166010
TITLE: Preparation of 4-phenoxyphenylacetic acids as glucocorticoid and thyroid hormone receptor ligands for the treatment of metabolic disorders
INVENTOR(S): Apelqvist, Theresa; Goede, Patrick; Holmgren, Erik
PATENT ASSIGNEE(S): Karo Bio AB, Swed.
SOURCE: PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000007972	A1	20000217	WO 1999-IB1447	19990804
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2339194	AA	20000217	CA 1999-2339194	19990804
AU 9951881	A1	20000228	AU 1999-51881	19990804
AU 753376	B2	20021017		
BR 9912742	A	20010502	BR 1999-12742	19990804
EP 1102739	A1	20010530	EP 1999-936913	19990804
EP 1102739	B1	20030423		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
SI 20579	C	20011231	SI 1999-20064	19990804
JP 2002522407	T2	20020723	JP 2000-563607	19990804
AT 238267	E	20030515	AT 1999-936913	19990804
BG 105214	A	20011231	BG 2001-105214	20010202
NO 2001000610	A	20010404	NO 2001-610	20010205
US 6492424	B1	20021210	US 2001-744865	20010409

PRIORITY APPLN. INFO.: GB 1998-16935 A 19980805
WO 1999-IB1447 W 19990804
OTHER SOURCE(S): MARPAT 132:166010
GI

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



I

AB The title compds. [I; R1 = alkyl, aryl, CO2H, etc.; R2, R3 = H, halo, alkyl, etc. (at least one of R2 and R3 being other than hydrogen); X = CO, CH2; R4 = alkyl, aryl, heteroaryl; R5 = halo, alkyl, cycloalkyl; Y = OH, OMe, NH2, alkylamino; n = 0-4], useful for treating diseases assocd. with metab. dysfunction or which are dependent on the expression of a glucocorticoid or thyroid receptor gene (such as diabetes, hypercholesterolemia, or obesity) (no data), were prepd. E.g., a multi-step synthesis of ester I [R1 = CO2Me; n = 1; R2 = R3 = Br; Y = OMe; R4 = Ph; X = CO; R5 = iso-Pr] was given. Compds. I are effective at 0.5-25 mg/kg/day.
IT 252043-61-1P 252201-98-2P 258819-45-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of 4-phenoxyphenylacetic acids as glucocorticoid and thyroid hormone receptor ligands for the treatment of metabolic disorders)
RN 252043-61-1 CAPLUS
CN Benzeneacetic acid, 4-[2-benzoyl-4-methoxy-5-(1-methylethyl)phenoxy]-3,5-dibromo-, methyl ester (9CI) (CA INDEX NAME)



RN 252201-98-2 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-methoxy-2-(3-methylbenzoyl)-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 258819-45-3 CAPLUS
CN Benzeneacetic acid, 4-[2-benzoyl-4-hydroxy-5-(1-methylethyl)phenoxy]-3,5-dibromo-, methyl ester (9CI) (CA INDEX NAME)



IT 258819-43-1P 258819-47-5P 258819-50-0P
258819-51-1P 258819-53-3P 258819-56-6P
258819-57-7P 258819-58-8P 258819-59-9P
258819-60-2P 258819-61-3P 258819-62-4P
258819-63-5P 258819-64-6P 258819-65-7P
258819-66-8P 258819-67-9P 258819-68-0P
258819-69-1P 258819-73-7P 258819-74-8P
258819-75-9P 258819-76-0P 258819-77-1P
258819-78-2P 258819-79-3P 258819-80-6P
258819-81-7P 258819-82-8P 258819-83-9P
258819-91-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 4-phenoxyphenylacetic acids as glucocorticoid and thyroid hormone receptor ligands for the treatment of metabolic disorders)
RN 258819-43-1 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[(4-chlorophenyl)acetyl]-4-methoxy-5-(1-methylethyl)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 258819-47-5 CAPLUS
CN Benzeneacetic acid, 4-[2-benzoyl-4-hydroxy-5-(1-methylethyl)phenoxy]-3,5-dibromo- (9CI) (CA INDEX NAME)



RN 258819-50-0 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[4-(1,1-dimethylethyl)benzoyl]-4-hydroxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 258819-51-1 CAPLUS
CN Benzeneacetic acid, 4-[2-benzoyl-4-methoxy-5-(1-methylethyl)phenoxy]-3,5-dibromo- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 258819-53-3 CAPLUS
CN Benzeneacetic acid, 4-[4-methoxy-5-(1-methylethyl)-2-(phenylmethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 258819-56-6 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-(2-fluorobenzoyl)-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 258819-57-7 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-(3-fluorobenzoyl)-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 258819-61-3 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-(diphenylacetyl)-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 258819-62-4 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-(3-chlorobenzoyl)-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 258819-63-5 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-(4-chlorobenzoyl)-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 258819-58-8 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-(4-fluorobenzoyl)-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 258819-59-9 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-methoxy-2-(2-methylbenzoyl)-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 258819-60-2 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-methoxy-2-(4-methylbenzoyl)-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 258819-64-6 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-(3-bromobenzoyl)-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 258819-65-7 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-(3-iodobenzoyl)-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 258819-66-8 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-(4-iodobenzoyl)-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 258819-67-9 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-methoxy-5-(1-methylethyl)-2-(3-nitrobenzoyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 258819-68-0 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-methoxy-5-(1-methylethyl)-2-[3-(trifluoromethyl)benzoyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 258819-69-1 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-(3-hydroxybenzoyl)-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 258819-73-7 CAPLUS
CN Benzeneacetic acid, 4-[2-[3,5-bis(1,1-dimethylethyl)benzoyl]-4-methoxy-5-(1-methylethyl)phenoxy]-3,5-dibromo- (9CI) (CA INDEX NAME)



RN 258819-74-8 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-(3,5-difluorobenzoyl)-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 258819-75-9 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-methoxy-5-(1-methylethyl)-2-[(3-

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)
methylphenyl)methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 258819-76-0 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[(3-iodophenyl)methyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 258819-77-1 CAPLUS
CN Benzenepropanoic acid, 3,5-dibromo-4-[4-methoxy-2-(3-methylbenzoyl)-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 258819-78-2 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-methoxy-5-(1-methylethyl)-2-[3-(phenylethynyl)benzoyl]phenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 258819-79-3 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[3-[(3-hydroxyphenyl)ethynyl]benzoyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 258819-80-6 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-(3-ethynylbenzoyl)-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 258819-81-7 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[3-(3-hydroxy-1-propynyl)benzoyl]-4-methoxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 258819-82-8 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-methoxy-5-(1-methylethyl)-2-[3-(3-oxo-1-pentenyl)benzoyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 258819-83-9 CAPLUS
CN Benzeneacetamide, 3,5-dibromo-4-[4-methoxy-2-(3-methylbenzoyl)-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 258819-91-9 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-hydroxy-5-(1-methylethyl)-2-(phenylmethyl)phenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 258819-95-3 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-methoxy-5-(1-methylethyl)-2-(phenylmethyl)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 258819-96-4 CAPLUS
CN Benzeneacetic acid, 4-[4-methoxy-5-(1-methylethyl)-2-(phenylmethyl)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 258819-99-7 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-(2-fluorobenzoyl)-4-methoxy-5-(1-methylethyl)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



IT 252043-62-2P 258819-94-2P 258819-95-3P
258819-96-4P 258819-99-7P 258820-00-7P
258820-01-8P 258820-02-9P 258820-03-0P
258820-04-1P 258820-05-2P 258820-06-3P
258820-07-4P 258820-08-5P 258820-09-6P
258820-10-9P 258820-11-0P 258820-12-1P
258820-16-5P 258820-17-6P 258820-18-7P
258820-19-8P 258820-20-1P 258820-21-2P
258820-22-3P 258820-23-4P 258820-24-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of 4-phenoxyphenylacetic acids as glucocorticoid and thyroid hormone receptor ligands for the treatment of metabolic disorders)

RN 252043-62-2 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-methoxy-2-(3-methylbenzoyl)-5-(1-methylethyl)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 258819-94-2 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[4-(1,1-dimethylethyl)benzoyl]-4-hydroxy-5-(1-methylethyl)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 258820-00-7 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-(3-fluorobenzoyl)-4-methoxy-5-(1-methylethyl)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 258820-01-8 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-(4-fluorobenzoyl)-4-methoxy-5-(1-methylethyl)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 258820-02-9 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-methoxy-2-(2-methylbenzoyl)-5-(1-methylethyl)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 258820-03-0 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-methoxy-2-(4-methylbenzoyl)-5-(1-methylethyl)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 258820-04-1 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-(diphenylacetyl)-4-methoxy-5-(1-methylethyl)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 258820-05-2 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-(3-chlorobenzpyl)-4-methoxy-5-(1-methylethyl)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 258820-09-6 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-(4-iodobenzoyl)-4-methoxy-5-(1-methylethyl)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 258820-10-9 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-methoxy-5-(1-methylethyl)-2-(3-nitrobenzoyl)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 258820-11-0 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-methoxy-5-(1-methylethyl)-2-[3-(trifluoromethyl)benzoyl]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 258820-06-3 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-(4-chlorobenzoyl)-4-methoxy-5-(1-methylethyl)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 258820-07-4 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-(3-bromobenzoyl)-4-methoxy-5-(1-methylethyl)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 258820-08-5 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-(3-iodobenzoyl)-4-methoxy-5-(1-methylethyl)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 258820-12-1 CAPLUS
CN Benzeneacetic acid, 4-[2-[3-(acetyloxy)benzoyl]-4-methoxy-5-(1-methylethyl)phenoxy]-3,5-dibromo-, methyl ester (9CI) (CA INDEX NAME)



RN 258820-16-5 CAPLUS
CN Benzeneacetic acid, 4-[2-[3,5-bis(1,1-dimethylethyl)benzoyl]-4-methoxy-5-(1-methylethyl)phenoxy]-3,5-dibromo-, methyl ester (9CI) (CA INDEX NAME)



RN 258820-17-6 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-(3,5-difluorobenzoyl)-4-methoxy-5-(1-methylethyl)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 258820-18-7 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[(3-iodophenyl)methyl]-4-methoxy-5-(1-methylethyl)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 258820-19-8 CAPLUS
CN Benzenepropanoic acid, 3,5-dibromo-4-[4-methoxy-2-(3-methylbenzoyl)-5-(1-methylethyl)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 258820-23-4 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[3-(3-hydroxy-1-propynyl)benzoyl]-4-methoxy-5-(1-methylethyl)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 258820-24-5 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-methoxy-5-(1-methylethyl)-2-[3-(3-oxo-1-penteny1)benzoyl]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 258820-20-1 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-methoxy-5-(1-methylethyl)-2-[3-(phenylethynyl)benzoyl]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 258820-21-2 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[2-[3-[(3-hydroxyphenyl)ethynyl]benzoyl]-4-methoxy-5-(1-methylethyl)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 258820-22-3 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-methoxy-5-(1-methylethyl)-2-[3-[(trimethylsilyl)ethynyl]benzoyl]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1999:795634 CAPLUS
DOCUMENT NUMBER: 132:30840
TITLE: KB 285 in treatment of diabetes
INVENTOR(S): Apelqvist, Theresa; Efendic, Suad
PATENT ASSIGNEE(S): Karo Bio AB, Swed.
SOURCE: PCT Int. Appl., 20 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9963976	A2	19991216	WO 1999-IB1175	19990607
WO 9963976	A3	20011220		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2334116	AA	19991216	CA 1999-2334116	19990607
AU 9941606	A1	19991230	AU 1999-41606	19990607
AU 751569	B2	20020822		
EP 1143948	A2	20011017	EP 1999-925232	19990607
EP 1143948	A3	20020911		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002527355	T2	20020827	JP 2000-553045	19990607

PRIORITY APPLN. INFO.: GB 1998-12314 A 19980608
GB 1998-15149 A 19980713
WO 1999-IB1175 W 19990607

GI



AB A liver-selective glucocorticoid antagonist, preferably KB285 (I) is prepd. and used in the prepn. of a pharmaceutical compns. for the treatment of diabetes. In addn. to synthetic examples, receptor binding

L4 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)
and cell based assays are given.
IT 252201-98-2P, KB 285
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(KB 285 in treatment of diabetes)
RN 252201-98-2 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-methoxy-2-(3-methylbenzoyl)-5-(1-mathylethyl)phenoxy]- (9CI) (CA INDEX NAME)



IT 252043-61-1P 252043-62-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(KB 285 in treatment of diabetes)
RN 252043-61-1 CAPLUS
CN Benzeneacetic acid, 4-[2-benzoyl-4-methoxy-5-(1-methylethyl)phenoxy]-3,5-dibromo-, methyl ester (9CI) (CA INDEX NAME)



RN 252043-62-2 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-methoxy-2-(3-methylbenzoyl)-5-(1-methylethyl)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	27.63	176.39

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.91	-3.91

STN INTERNATIONAL LOGOFF AT 15:57:05 ON 25 JUN 2003

(2)

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 O,S,N,CH2,CH,CF2,SO2,NH

G2 O,S

G3 O,N

G4 C,S,N,CH,CF2,Ak

G5 H,Et,n-Pr,i-Pr,n-Bu,i-Bu,s-Bu,t-Bu,Me

G6

G7 H,CN,X,Cb,Ak,CH2,CH,CF2,CF3

G8 H,Ak

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 15:32:52 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 18163 TO ITERATE

5.5% PROCESSED 1000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 355203 TO 371317
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 15:33:02 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 360323 TO ITERATE

100.0% PROCESSED 360323 ITERATIONS 78 ANSWERS

SEARCH TIME: 00.00.10

L3 78 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	148.55	148.76

FILE 'CAPLUS' ENTERED AT 15:33:20 ON 25 JUN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 25 Jun 2003 VOL 138 ISS 26
FILE LAST UPDATED: 24 Jun 2003 (20030624/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 20 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 20 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2003:173554 CAPLUS
DOCUMENT NUMBER: 138:221353
TITLE: Preparation of aryloxyphenols as thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
INVENTOR(S): Malm, Johan; Brandt, Peter; Edvinsson, Karin; Koehler, Konrad; Sanin, Andrei; Gordon, Sandra
PATENT ASSIGNEE(S): Karo Bio AB, Swed.
SOURCE: PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003018515	A2	20030306	WO 2002-EP9120	20020813

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:	GB 2001-20691	A	20010824
	GB 2002-7719	A	20020403

OTHER SOURCE(S): MARPAT 138:221353
GI



I



II

AB Title compds. I (R1 = carboxy, ester, .alpha.-hydroxycarboxy, etc.; R2-3 = Cl, I, Br, alkyl, haloalkyl, alkenyl, etc.; R4 = halo, alkyl, alkenyl, alkynyl, etc.; X = CH2CH2, CH2CH2CH2, CH=CH, etc.; R5 = (hetero)aryl, cycloalkyl, etc.; n = 0-2) are prepd. For instance, Me 3,5-dibromo-4-(3-isopropyl-4-methoxyphenoxy)benzoate is nitrated (PhH, HNO3), reduced (EtOH, Na2S2O4) and converted to Me 3,5-dibromo-4-(3-iodo-5-isopropyl-4-methoxyphenoxy)benzoate (MeOH, HCl, KI). This intermediate was sapond. (EtOH, KOH), demethylated (CH2Cl2, BF3.bul.SMe2) and coupled to styrene (DMF, Et3N, Me3NCH2PhCl, tris(dibenzylideneacetone)dipalladium) to give II. The compds. of the invention exhibit binding affinities to the ThR.alpha. receptor in the range of 10 to 500 nM. I are useful in the treatment of cardiac and metabolic disorders, such as cardiac arrhythmias, thyrotoxicosis, subclin. hyperthyroidism and liver diseases.

IT 500794-84-3P 500794-95-6P, (E)-3-[3,5-Dibromo-4-[3-[2-(4-((dimethylamino)methyl]phenyl)ethenyl]-4-hydroxy-5-isopropylphenoxy]phenyl]propionic acid 500794-97-8P, (E)-4-[2-[5-[2,6-Dibromo-4-(2-carboxyethyl)phenoxy]-2-hydroxy-3-isopropylphenyl]ethenyl]benzoic acid 500795-00-6P, 3-[3,5-Dibromo-4-(4-hydroxy-3-isopropyl-5-(phenethyl)phenoxy)phenyl]propionic acid 500795-02-8P, (E)-3-[3,5-Dibromo-4-(4-hydroxy-3-isopropyl-5-(2-phenylethenyl)phenoxy)phenyl]-2-hydroxypropionic acid 500795-11-9P, 3-[3,5-Dibromo-4-(4-hydroxy-3-isopropyl-5-(phenethyl)phenoxy)phenyl]-2-hydroxypropionic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(aryloxyphenols as thyroid receptor antagonists for treatment of cardiac and metabolic disorders)

RN 500794-84-3 CAPLUS
CN Benzenepropanoic acid, 3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)-5-[(1E)-2-phenylethenyl]phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 500794-95-6 CAPLUS
CN Benzenepropanoic acid, 3,5-dibromo-4-[3-[(1E)-2-[4-((dimethylamino)methyl]phenyl]ethenyl]-4-hydroxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 500794-97-8 CAPLUS
CN Benzenepropanoic acid, 3,5-dibromo-4-[3-[(1E)-2-(4-carboxyphenyl)ethenyl]-4-hydroxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 500795-00-6 CAPLUS
CN Benzenepropanoic acid, 3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)-5-(2-phenylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 500795-02-8 CAPLUS
CN Benzenepropanoic acid, 3,5-dibromo-.alpha.-hydroxy-4-[4-hydroxy-3-(1-methylethyl)-5-[(1E)-2-phenylethenyl]phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 500795-11-9 CAPLUS
CN Benzenepropanoic acid, 3,5-dibromo-.alpha.-hydroxy-4-[4-hydroxy-3-(1-methylethyl)-5-(2-phenylethyl)phenoxy]- (9CI) (CA INDEX NAME)



L4 ANSWER 1 OF 20 CAPLUS COPYRIGHT 2003 ACS (Continued)

IT 500795-01-7P, Methyl (E)-3-[3,5-dibromo-4-[4-hydroxy-3-isopropyl-5-(2-phenylethenyl]phenoxy]phenyl]propionate 500795-08-4P, Methyl (E)-3-[3,5-dibromo-4-[4-hydroxy-3-isopropyl-5-(2-phenylethenyl]phenoxy]phenyl]-2-hydroxypropionate 500795-12-0P, Methyl 3-[3,5-dibromo-4-(4-hydroxy-3-isopropyl-5-(phenethyl]phenoxy]phenyl]-2-hydroxypropionate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(aryloxyphenols as thyroid receptor antagonists for treatment of cardiac and metabolic disorders)

RN 500795-01-7 CAPLUS
CN Benzenepropanoic acid, 3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)-5-[(1E)-2-phenylethenyl]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 500795-08-4 CAPLUS
CN Benzenepropanoic acid, 3,5-dibromo-.alpha.-hydroxy-4-[4-hydroxy-3-(1-methylethyl)-5-[(1E)-2-phenylethenyl]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 500795-12-0 CAPLUS
CN Benzenepropanoic acid, 3,5-dibromo-.alpha.-hydroxy-4-[4-hydroxy-3-(1-methylethyl)-5-(2-phenylethyl)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 20 CAPLUS COPYRIGHT 2003 ACS (Continued)



L4 ANSWER 2 OF 20 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:721656 CAPLUS
DOCUMENT NUMBER: 138:280956
TITLE: A thyroid hormone antagonist that inhibits thyroid hormone action in vivo
AUTHOR(S): Lim, Wayland; Nguyen, Ngoc-Ha; Yang, Ha Yung; Scanlan, Thomas S.; Furlow, J. David
CORPORATE SOURCE: Sect. Neurobiol., Physiol, Behavior, University of California, Davis, CA, 95616-8519, USA
SOURCE: Journal of Biological Chemistry (2002), 277(38), 35664-35670
CODEN: JBCHA3; ISSN: 0021-9258
PUBLISHER: American Society for Biochemistry and Molecular Biology
DOCUMENT TYPE: Journal
LANGUAGE: English

AB We have characterized the newly developed thyroid hormone antagonist NH-3 in both cell culture and in vivo model systems. NH-3 binds Xenopus laevis thyroid hormone receptors directly in vitro and induces a conformation distinct from agonist-bound receptors. Transcriptional activation of a thyroid hormone response element-contg. reporter gene is strongly inhibited by NH-3 in a dose-dependent manner. In addn., NH-3 prevents X. laevis thyroid hormone receptors from binding to the p160 family of co-activators GRIP-1 and SRC-1 in a two-hybrid assay. To assess the potency of the compd. in vivo, we used induced and spontaneous X. laevis tadpole metamorphosis, a thyroid hormone-dependent developmental process. NH-3 inhibits thyroid hormone-induced morphol. changes in a dose-dependent manner and inhibits the up-regulation of endogenous thyroid hormone-responsive genes. Spontaneous metamorphosis is efficiently and reversibly arrested by NH-3 with at least the same effectiveness as the thyroid hormone synthesis inhibitor methimazole. Therefore, NH-3 is the first thyroid hormone antagonist to demonstrate potent inhibition of thyroid hormone action in both cell culture- and whole animal-based assays.

IT 447415-26-1
RL: BSU (Biological study, unclassified); DMA (Drug mechanism of action); PAC (Pharmacological activity); BIOL (Biological study)
(thyroid hormone antagonist that inhibits thyroid hormone action in vivo)

RN 447415-26-1 CAPLUS
CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)-5-[(4-nitrophenyl)ethynyl]phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS

L4 ANSWER 2 OF 20 CAPLUS COPYRIGHT 2003 ACS (Continued)
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 20 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:716241 CAPLUS
DOCUMENT NUMBER: 137:232450
TITLE: Preparation of biphenyl derivatives as thyroid hormone analogs
INVENTOR(S): Haning, Helmut; Woltering, Michael; Schmidt, Gunter; Faeste, Christiane; Bischoff, Hilmar; Kretschmer, Axel; Voehringer, Verena; Ellinghaus, Peter
PATENT ASSIGNEE(S): Bayer Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 95 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002072539	A1	20020919	WO 2002-EP2065	20020227
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10130835	A1	20020919	DE 2001-10130835	20010627
US 2003105078	A1	20030605	US 2002-82022	20020226

PRIORITY APPLN. INFO.: DE 2001-10111651 A 20010312
DE 2001-10130835 A 20010627
OTHER SOURCE(S): MARPAT 137:232450
GI



I

AB Title compds. [I; X = O, S, SO2, CH2, CHF, CF2, NR8; R8 = H, alkyl; R1, R2 = H, alkyl; R3, R4 = H, halo, cyano, alkyl, CF3, CHF2, CH2F, vinyl, cycloalkyl; R5 = H, alkyl, halo; R6 = SR9, S(O)nR10, NR11C(O)R12, CH2, etc.; R9 = alkyl, cycloalkyl, alkenyl, aryl, arylmethyl, etc.; n = 1, 2; R10 = OR15, NR16R17, alkyl, cycloalkyl, etc.; R15 = H, Ph, benzyl, alkyl, etc.; R16, R17 = H, (branched) (substituted) alkyl, etc; R11 = H, (branched) (substituted) alkyl, etc.; R12 = (branched) (substituted) alkyl, etc.; R7 = H, alkyl, alkanoyl; Z = YmWCOR36; Y = O, S; m = 0, 1; W = (substituted) alkylene; R36 = OR37, NR38R39; R37-R39 = H, Ph, benzyl, alkyl, etc.], were prepd. as thyroid hormone analogs (no data). Thus, Et [4-(4-[benzyloxy]-3-[(4-fluorophenyl)sulfonyl]benzyl)-3,5-dimethylphenoxy]acetate (prepn. given) in EtOH was hydrogenated in the presence of Pd/activated C for 2 h at room temp. and 1013 mbar to give 86% Et [4-(3-[(4-fluorophenyl)sulfonyl]-4-hydroxybenzyl)-3,5-dimethylphenoxy]acetate which was sapond. with 1 N NaOH in EtOH to give 90% [4-(3-[(4-fluorophenyl)sulfonyl]-4-hydroxybenzyl)-3,5-dimethylphenoxy]acetic acid. The compds. I are esp. suitable for use in any indications that may be treated with natural thyroid hormones such as depression or thyroid tumor. The inventive compds. I are preferably used to treat arteriosclerosis, hypercholesterolemia, dyslipidemia as well as obesity.

IT 459431-01-7P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of biphenyl derivs. as thyroid hormone analogs)
RN 459431-01-7 CAPLUS
CN Acetic acid, [4-[[3-[(4-fluorophenyl)sulfonyl]-4-hydroxyphenyl]methyl]-3,5-dimethylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



IT 459431-02-8P 459431-03-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of biphenyl derivs. as thyroid hormone analogs)
RN 459431-02-8 CAPLUS
CN Acetic acid, [4-[[3-[(4-fluorophenyl)sulfonyl]-4-hydroxyphenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)



RN 459431-03-9 CAPLUS

L4 ANSWER 3 OF 20 CAPLUS COPYRIGHT 2003 ACS (Continued)
CN Propanoic acid, 2-[4-[[3-[(4-fluorophenyl)sulfonyl]-4-hydroxyphenyl]methyl]-3,5-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



IT 459430-99-0P 459431-00-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of biphenyl derivs. as thyroid hormone analogs)
RN 459430-99-0 CAPLUS
CN Acetic acid, [4-[[3-[(4-fluorophenyl)sulfonyl]-4-(phenylmethoxy)phenyl]methyl]-3,5-dimethylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 459431-00-6 CAPLUS
CN Propanoic acid, 2-[4-[[3-[(4-fluorophenyl)sulfonyl]-4-(phenylmethoxy)phenyl]methyl]-3,5-dimethylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 20 CAPLUS COPYRIGHT 2003 ACS (Continued)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 20 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:457917 CAPLUS
DOCUMENT NUMBER: 137:169293
TITLE: Rational Design and Synthesis of a Novel Thyroid Hormone Antagonist That Blocks Coactivator Recruitment
AUTHOR(S): Nguyen, Ngoc-Ha; Apriletti, James W.; Lima, Suzana T. Cunha; Webb, Paul; Baxter, John D.; Scanlan, Thomas S.
CORPORATE SOURCE: Program in Chemistry and Chemical Biology, Departments of Pharmaceutical Chemistry and Cellular and Molecular Pharmacology, University of California, San Francisco, CA, 94143-0446, USA
SOURCE: Journal of Medicinal Chemistry (2002), 45(15), 3310-3320
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 137:169293
GI



I



II

AB The authors report the design and synthesis of a novel series of phenylethynyl derivs. I [R = H, (CH2)4Me, NO2, NH2] sharing the halogen-free thyronine scaffold of GC-1 (II). I (R = NO2) is a T3 antagonist with negligible TR agonist activity and improved TR binding affinity and potency that allow for further characterization of its obsd. activity. Its ability to block TR-coactivator interactions appears to be the mechanism for antagonism. It will be a useful pharmacol. tool for further study of T3 signaling and TR function.

IT 447415-19-2P 447415-22-7P 447415-26-1P
447415-29-4P
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation);

L4 ANSWER 4 OF 20 CAPLUS COPYRIGHT 2003 ACS (Continued)
methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)



IT 446312-33-0P 446312-34-1P 446312-36-3P
446312-37-4P 446312-38-5P 446312-39-6P
446312-40-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of phenylethynyl derivs. of GC-1 as thyroid hormone analogs and their binding activity towards thyroid hormone receptors)

RN 446312-33-0 CAPLUS
CN Acetic acid, [4-[[4-(methoxymethoxy)-3-(1-methylethyl)-5-(phenylethynyl)phenyl]methyl]-3,5-dimethylphenoxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 446312-34-1 CAPLUS
CN Acetic acid, [4-[[4-(methoxymethoxy)-3-(1-methylethyl)-5-[(4-pentylphenyl)ethynyl]phenyl]methyl]-3,5-dimethylphenoxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 446312-36-3 CAPLUS
CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)-5-[(4-pentylphenyl)ethynyl]phenyl]methyl]-3,5-dimethylphenoxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 20 CAPLUS COPYRIGHT 2003 ACS (Continued)
BIOL (Biological study); PREP (Preparation)
(prepn. of phenylethynyl derivs. of GC-1 as thyroid hormone analogs and their binding activity towards thyroid hormone receptors)

RN 447415-19-2 CAPLUS
CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)-5-[(4-phenylethynyl)phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)



RN 447415-22-7 CAPLUS
CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)-5-[(4-pentylphenyl)ethynyl]phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)



RN 447415-26-1 CAPLUS
CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)-5-[(4-nitrophenyl)ethynyl]phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)



RN 447415-29-4 CAPLUS
CN Acetic acid, [4-[[3-[(4-aminophenyl)ethynyl]-4-hydroxy-5-(1-

L4 ANSWER 4 OF 20 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 446312-37-4 CAPLUS
CN Acetic acid, [4-[[3-[(4-aminophenyl)ethynyl]-4-(methoxymethoxy)-5-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 446312-38-5 CAPLUS
CN Acetic acid, [4-[[4-(methoxymethoxy)-3-(1-methylethyl)-5-[(4-nitrophenyl)ethynyl]phenyl]methyl]-3,5-dimethylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 446312-39-6 CAPLUS
CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)-5-[(4-nitrophenyl)ethynyl]phenyl]methyl]-3,5-dimethylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 20 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 446312-40-9, CAPLUS
CN Acetic acid, [4-[[3-[(4-aminophenyl)ethynyl]-4-hydroxy-5-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L4 ANSWER 5 OF 20 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2000:117013 CAPLUS
DOCUMENT NUMBER: 132:166010
TITLE: Preparation of 4-phenoxyphenylacetic acids as glucocorticoid and thyroid hormone receptor ligands for the treatment of metabolic disorders
INVENTOR(S): Apelqvist, Theresa; Goede, Patrick; Holmgren, Erik
PATENT ASSIGNEE(S): Karo Bio AB, Swed.
SOURCE: PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000007972	A1	20000217	WO 1999-IB1447	19990804
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2339194	AA	20000217	CA 1999-2339194	19990804
AU 9951881	A1	20000228	AU 1999-51881	19990804
AU 753376	B2	20021017		
BR 9912742	A	20010502	BR 1999-12742	19990804
EP 1102739	A1	20010530	EP 1999-936913	19990804
EP 1102739	B1	20030423		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
SI 20579	C	20011231	SI 1999-20064	19990804
JP 2002522407	T2	20020723	JP 2000-563607	19990804
AT 238267	E	20030515	AT 1999-936913	19990804
BG 105214	A	20011231	BG 2001-105214	20010202
NO 2001000610	A	20010404	NO 2001-610	20010205
US 6492424	B1	20021210	US 2001-744865	20010409

PRIORITY APPLN. INFO.: GB 1998-16935 A 19980805
WO 1999-IB1447 W 19990804
OTHER SOURCE(S): MARPAT 132:166010
GI

L4 ANSWER 5 OF 20 CAPLUS COPYRIGHT 2003 ACS (Continued)



AB The title compds. [I; R1 = alkyl, aryl, CO2H, etc.; R2, R3 = H, halo, alkyl, etc. (at least one of R2 and R3 being other than hydrogen); X = CO, CH2; R4 = alkyl, aryl, heteroaryl; R5 = halo, alkyl, cycloalkyl; Y = OH, OMe, NH2, alkylamino; n = 0-4], useful for treating diseases assocd. with metab. dysfunction or which are dependent on the expression of a glucocorticoid or thyroid receptor gene (such as diabetes, hypercholesterolemia, or obesity) (no data), were prepd. E.g., a multi-step synthesis of ester I [R1 = CO2Me; n = 1; R2 = R3 = Br; Y = OMe; R4 = Ph; X = CO; R5 = iso-Pr] was given. Compds. I are effective at 0.5-25 mg/kg/day.
IT 258819-48-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 4-phenoxyphenylacetic acids as glucocorticoid and thyroid hormone receptor ligands for the treatment of metabolic disorders)
RN 258819-48-6 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)-5-(phenylmethyl)phenoxy]- (9CI) (CA INDEX NAME)



IT 258820-36-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of 4-phenoxyphenylacetic acids as glucocorticoid and thyroid hormone receptor ligands for the treatment of metabolic disorders)
RN 258820-36-9 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-methoxy-3-(1-methylethyl)-5-(phenylmethyl)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 20 CAPLUS COPYRIGHT 2003 ACS (Continued)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L4 ANSWER 6 OF 20 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1996:629766 CAPLUS
DOCUMENT NUMBER: 125:261263
TITLE: Positive-working resists containing t-butoxycarbonylmethyloxybenzene dissolution inhibitor
for suppressed alkaline impurity
INVENTOR(S): Watanabe, Atsushi; Ishihara, Toshinobu; Yagihashi, Fujio; Tanaka, Haruyori; Kawai, Yoshio; Nakamura, Jiro
PATENT ASSIGNEE(S): Shinetsu Chem Ind Co, Japan; Nippon Telegraph & Telephone
SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08194313	A2	19960730	JP 1995-20958	19950113
PRIORITY APPLN. INFO.:			JP 1995-20958	19950113

OTHER SOURCE(S): MARPAT 125:261263
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The pos. resists comprise 3 components of an acid generator, a polymer compd., and a dissoln. inhibitor selected from 1,4-bis[bis(4-t-butoxycarbonylmethyloxyphenyl)methyl]benzene, its deriv. I (R1-2 = alkyl; k = 0-4; l = 0-2, k + l .ltoreq.4), 1,3-bis(4-t-butoxycarbonylmethyloxyphenylmethyl)-4,6-bis-t-butoxycarbonylmethyloxybenzene, its deriv. II (R = H, alkyl), bis(4-t-butoxycarbonylmethyloxy-2,5-dimethylphenyl)methyl-4-t-butoxycarbonylmethyloxybenzene, its deriv. III (R = alkyl; m = 0-4), 2,2-bis(2,4-di-t-butoxycarbonylmethyloxyphenyl)propane, its deriv. IV (R4 = alkyl; m = 0-3), 2,6-bis(2-t-butoxycarbonylmethyloxyphenylmethyl)-1-t-butoxycarbonylmethyloxy-4-methylbenzene, and its deriv. V (R = alkyl; n = 0, 1; m = 0-(4- n)). The dissoln. inhibitor suppresses penetration of an alk. impurity in the resist film and provides high-resoln. images.
IT **182216-21-3 182216-26-8 182261-28-5**
RL: TEM (Technical or engineered material use); USES (Uses)
(pos. resists contg. t-butoxycarbonylmethyloxybenzene dissoln. inhibitor for suppressed alk. impurity)
RN 182216-21-3 CAPLUS
CN Acetic acid, 2,2'-[[4,6-bis[2-(1,1-dimethylethoxy)-2-oxoethoxy]-1,3-phenylene]bis(methylene-4,1-phenyleneoxy)]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 20 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 182216-26-8 CAPLUS
CN Acetic acid, 2,2'-[[4,6-bis[2-(1,1-dimethylethoxy)-2-oxoethoxy]-5-methyl-1,3-phenylene]bis(methylene-4,1-phenyleneoxy)]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 182261-28-5 CAPLUS
CN Acetic acid, 2,2'-[[4-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-1,3-phenylene]bis[methylene(2,5-dimethyl-4,1-phenylene)oxy]]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



L4 ANSWER 7 OF 20 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1996:628058 CAPLUS
DOCUMENT NUMBER: 125:261266
TITLE: 1,3-Bis(4-tert-butoxycarbonylmethyloxyphenylmethyl)-4,6-bis-tert-butoxycarbonylmethyloxybenzene derivative
for dissolution inhibitor of three-component resist
INVENTOR(S): Watanabe, Atsushi; Ishihara, Toshinobu; Yagihashi, Fujio
PATENT ASSIGNEE(S): Shinetsu Chem Ind Co, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 4 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08193053	A2	19960730	JP 1995-20954	19950113
PRIORITY APPLN. INFO.:			JP 1995-20954	19950113

OTHER SOURCE(S): MARPAT 125:261266
GI



I

AB The deriv. is I (R = H, alkyl). The deriv. shows good soly. toward macromol. compd. in a three-component pos.-working resist, and is useful for dissoln. inhibitor of the resist.
IT **182216-21-3P 182216-26-8P**
RL: PNU (Preparation, unclassified); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)
(prepn. of bis(carbonylmethyloxyphenylmethyl)benzene deriv. for dissoln. inhibitor of three-component resist)
RN 182216-21-3 CAPLUS
CN Acetic acid, 2,2'-[[4,6-bis[2-(1,1-dimethylethoxy)-2-oxoethoxy]-1,3-phenylene]bis(methylene-4,1-phenyleneoxy)]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

L4 ANSWER 7 OF 20 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 182216-26-8 CAPLUS
CN Acetic acid, 2,2'-[[4,6-bis[2-(1,1-dimethylethoxy)-2-oxoethoxy]-5-methyl-1,3-phenylene]bis(methylene-4,1-phenyleneoxy)]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



L4 ANSWER 8 OF 20 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1996:126694 CAPLUS
DOCUMENT NUMBER: 124:160416
TITLE: Positive photosensitive composition
INVENTOR(S): Aoai, Toshiaki; Yamanaka, Tsukasa
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 81 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 691575	A2	19960110	EP 1995-110358	19950703
EP 691575	A3	19960515		
EP 691575	B1	20020320		
R: BE, DE				
JP 08015862	A2	19960119	JP 1994-152218	19940704
JP 3290303	B2	20020610		
JP 08022126	A2	19960123	JP 1994-157278	19940708
JP 3290305	B2	20020610		
JP 08029982	A2	19960202	JP 1994-160143	19940712
JP 3337827	B2	20021028		
US 5824451	A	19981020	US 1995-497795	19950703

PRIORITY APPLN. INFO.: JP 1994-152218 A 19940704
JP 1994-157278 A 19940708
JP 1994-160143 A 19940712

AB A pos. photosensitive compn. comprises (a) a resin sol. in an aq. alkali soln. contg. a specific structure unit, (b) a compd. which generates an acid with irradn. of an active ray or radiation, and (c) a low-mol.-wt. acid-decomposable dissoln. inhibitor having a mol. wt. of not more than 3000, which possesses a tertiary alkyl ester group and whose soly. in an aq. alkali soln. is increased by the action of an acid, wherein compd. (c) is a compd. having at least two tertiary alkyl ester groups, in which the longest distance with respect to the distance between two tertiary ester groups selected arbitrarily comprises at least 10 bonding atoms except for the atoms contained in the ester groups or a compd. having at least three tertiary alkyl ester groups, in which the longest distance with respect to the distance between two tertiary ester groups. The pos. photosensitive compn. has a high sensitivity, high resoln. and good profile and excels in storage stability and heat resistance of the resist soln.

IT **173786-59-9P**
RL: SPN (Synthetic preparation); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)
(prepn. and use in pos. photosensitive compns. for lithog. plate manuf.)

RN 173786-59-9 CAPLUS
CN Acetic acid, 2,2',2'',2'''-[(1-methylethylidene)bis[[2-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-5,1,3-benzenetriyl]bis[methylene(2,6-dimethyl-

L4 ANSWER 8 OF 20 CAPLUS COPYRIGHT 2003 ACS (Continued)
4,1-phenylene)oxy]]]tetrakis-, tetrakis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L4 ANSWER 9 OF 20 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1996:50352 CAPLUS
DOCUMENT NUMBER: 124:101865
TITLE: Positive-working photoresist composition
INVENTOR(S): Yamanaka, Tsukasa; Sakaguchi, Shinji; Kokubo, Tadayoshi; Kawabe, Yasumasa
PATENT ASSIGNEE(S): Fuji Photo Film Co Ltd, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 53 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07271037	A2	19951020	JP 1994-63862	19940331

PRIORITY APPLN. INFO.: JP 1994-63862 19940331
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compn. comprises an alkali sol. resin, a photoacid generator, and .gtoreq.1 kinds of compds. selected from I and II (R1-41 = H, XRa1, CN, OD0; X1-10 = single bond, carbonyl, sulfido, sulfonyl, CRb1Rb2; X = single bond, O, S, CO, OCO, NRa1CO, NRa2; Ra1 = C1-10 alkyl, alkylene, cycloalkyl, haloalkyl, aryl, alkylaryl, aralkyl; Ra2 = H, Ra1; Rb1, Rb2 = H, Me, Et, C1-4 haloalkyl; D0-12 = H, Dinh; Dinh = XiRi; Xi = CRb1Rb2, CRb1Rb20, CO, CS, COO, COS, CRb1Rb2CO, CRb1Rb2COO, CRb10Ri, CONRb1; Ri = H, C1-20 alkyl, alkenyl, C3-20 cycloalkyl, C6-20 aryl, cumyl, adamantyl, SiZiRb3ZiRb4ZiRb5, tetrahydro-pyranyl, pyranyl, 1,3-dithia-indane-2-yl;Rb3-b5 = C1-20 alkyl, cycloalkyl, alkenyl, C6-20 aryl; Zi = single bond, O; i, j, k, m, n = 0, 1).

IT **172651-17-1P 172651-19-3P 172651-22-6P**
172651-25-1P 172651-26-2P 172651-28-4P
172651-31-9P 172651-32-0P
RL: DEV (Device component use); IMF (Industrial manufacture); PREP (Preparation); USES (Uses)
(pos.-working photoresist compn. comprising)

RN 172651-17-1 CAPLUS
CN Acetic acid, 2,2'-[[2-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-5-methyl-1,3-phenylene]bis[methylene(2,5-dimethyl-4,1-phenylene)oxy]]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

L4 ANSWER 9 OF 20 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 172651-19-3 CAPLUS
CN Acetic acid, 2,2'-[methylenebis[[2-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-5-methyl-3,1-phenylene]methylene-4,1-phenyleneoxy]]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L4 ANSWER 9 OF 20 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 2-A



RN 172651-22-8 CAPLUS
CN Acetic acid, 2,2'-[methylenebis[[6-[[4-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-2,5-dimethylphenyl]methyl]-4-methyl-2,1-phenylene]oxy]]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 172651-25-1 CAPLUS
CN Acetic acid, 2,2'-[[2-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-5-methyl-1,3-phenylene]bis[methylene[6-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-5-methyl-3,1-phenylene]methylene-4,1-phenyleneoxy]]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

L4 ANSWER 9 OF 20 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A



PAGE 1-B



RN 172651-26-2 CAPLUS
CN Acetic acid, 2,2'-[[2-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-5-methyl-1,3-phenylene]bis[methylene[6-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-2,5-dimethyl-3,1-phenylene]methylene-4,1-phenyleneoxy]]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

L4 ANSWER 9 OF 20 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A



PAGE 1-B



RN 172651-28-4 CAPLUS
CN Acetic acid, 2,2'-[methylenebis[[6-[[4-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-3-[[4-[2-(1,1-dimethylethoxy)-2-oxoethoxy]phenyl]methyl]-2,5-dimethylphenyl]methyl]-4-methyl-2,1-phenylene]oxy]]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

L4 ANSWER 9 OF 20 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A



PAGE 1-B



PAGE 2-A



RN 172651-31-9 CAPLUS
CN Acetic acid, 2,2'-[[2-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-5-methyl-1,3-phenylene]bis[methylene[6-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-2,5-dimethyl-3,1-phenylene]methylene[6-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-2,5-dimethyl-4,1-phenylene]methylene[2-methyl-4,1-phenylene]oxy]]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

L4 ANSWER 9 OF 20 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A



PAGE 1-B



RN 172651-32-0 CAPLUS
CN Acetic acid, 2,2'-[(2,5-dimethyl-1,3-phenylene)bis[methylene[6-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-2,5-dimethyl-3,1-phenylene]methylene[6-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-3,1-phenylene]methylene(2-methyl-4,1-phenylene)oxy]]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

L4 ANSWER 9 OF 20 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A



PAGE 1-B



L4 ANSWER 10 OF 20 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1994:450249 CAPLUS
DOCUMENT NUMBER: 121:50249
TITLE: Computer-assisted molecular modeling of benzodiazepine and thyromimetic inhibitors of the HepG2 iodothyronine membrane transporter
AUTHOR(S): Kragie, Laura; Forrester, Maureen L.; Cody, Vivian; McCourt, Mary
CORPORATE SOURCE: Fac. Nat. Sci. Math., State Univ. New York, Buffalo, Amherst, NY, 14260, USA
SOURCE: Molecular Endocrinology (1994), 8(3), 382-91
CODEN: MOENEN; ISSN: 0888-8809
DOCUMENT TYPE: Journal
LANGUAGE: English

AB T3 cellular uptake is inhibited in the presence of benzodiazepines (BZs). The structure-activity relationship of BZ inhibition correlates strongly with halogen substitution of the nonfused Ph ring and indicates that this ring is required for activity. A structure-activity series of thyromimetic (TH) inhibitors of the HepG2 iodothyronine transporter further point out the crit. importance of the amino group of the alanine side chain, its L-stereo configuration, and the size of the substituents of the inner and outer Ph rings. A third series of compds., reported to interact at related sites, were inactive as HepG2 iodothyronine transport inhibitors, and therefore the potent inhibitors were restricted to the BZ and TH compds. Using both of these BZ and TH structure-activity series along with computer-assisted mol. modeling techniques, the authors detd. which chem. structural components were important at the transporter interaction site. By superimposing structures from active chems., excluding residues from poor inhibitors, and incorporating mol. electropotential data, the authors developed a five-point model of BZ conformational similarity to the endogenous transporter ligand, L-T3: the alkyl substitution at the N1 of the BZ ring seems to stimulate the alanine side chain of T3, and the electroneg. halogen and oxygen atoms of substituents at R3/R7/R2'/R4' of BZ form a pyrimidyl pharmacophore that seems to correspond with the 3-1/5-1/3'-1/4'-OH substituents of T3, resp. These points, suggesting a tilted cross-bow formation, may be sites for ligand interaction with the iodothyronine transporter.

IT 105170-31-8, SKF-L 93236
RL: BIOL (Biological study)
(triiodothyronine binding by iodothyronine transporter inhibition by, structure in relation to)

RN 105170-31-8 CAPLUS
CN L-Tyrosine, O-[4-hydroxy-3-[(4-hydroxyphenyl)methyl]phenyl]-3,5-diiodo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 10 OF 20 CAPLUS COPYRIGHT 2003 ACS (Continued)

L4 ANSWER 11 OF 20 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1994:435024 CAPLUS
DOCUMENT NUMBER: 121:35024
TITLE: Preparation of 4-(3-cyclohexyl-4-hydroxy or-methoxyphenylsulfonyl)-3,5-dibromophenylacetic thyromimetic cholesterol-lowering agents
INVENTOR(S): Walker, Keith A.; Labadie, Sharada S.; Kertesz, Denis J.; Laughton, Craig W.
PATENT ASSIGNEE(S): Syntex (U.S.A.), Inc., USA
SOURCE: U.S., 15 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5284971	A	19940208	US 1992-914837	19920716
PRIORITY APPLN. INFO.:			US 1992-914837	19920716

OTHER SOURCE(S): MARPAT 121:35024
GI



I

AB Title compds. I (R1 = R9CO(CHNR7R8)m(CH2)n wherein n = 1-3, m = 0,1, R7, R8 = H, C1-4 alkyl, R9 = HO, C1-4 alkoxy, R8R7N; R3, R5 = Br, Cl, iodo, Me; R31 = H, Cl, Br, iodo, C1-4 alkyl, C4-6 cycloalkyl, C1-4 haloalkyl, C4-6 halocycloalkyl, Ar(R10)CH wherein Ar = 5-hydroxypyrid-2-yl, 6-hydroxypyrid-3-yl, 6-hydroxypyridazin-3-yl, 6-methoxypyridazin-3-yl, 6-hydroxypyridazin-3-yl N-oxide, 6-methoxypyridazin-3-yl N-oxide, R10 = H, C1-4 alkyl; R41 = HO, bioprecursor) and pharmaceutically acceptable salts thereof, useful as anticholesteremic agents (no data), are prepd. SO2Cl2 in CH2Cl2 was added to Me 3,5-dibromo-4-mercaptophenylacetate (prepn. given) followed by 2-(Me2CH)C6H4OMe to give Me 3,5-dibromo-4-[(3-isopropyl-4-methoxyphenyl)thio]phenylacetate which with m-ClC6H4CO2OH in CH2Cl2 was reacted for 20 h to give I (R1 = MeO2CCH2, R3 = R5 = Br, R31 = Me2CH, R41 = MeO). Pharmaceutical formulations comprising I are given.

IT 155780-54-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as anticholesteremic)

RN 155780-54-4 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[[4-hydroxy-3-[(4-hydroxyphenyl)methyl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 20 CAPLUS COPYRIGHT 2003 ACS (Continued)



L4 ANSWER 12 OF 20 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1989:635049 CAPLUS
DOCUMENT NUMBER: 111:235049
TITLE: Preparation of benzothiazinoanthraquinone derivatives as colorants for near-infrared filters, optical disk memory devices, and liquid crystal devices
INVENTOR(S): Morishita, Yasuyoshi
PATENT ASSIGNEE(S): Nippon Kayaku Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 11 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 64000076	A2	19890105	JP 1987-154333	19870623
PRIORITY APPLN. INFO.:			JP 1987-154333	19870623

OTHER SOURCE(S): MARPAT 111:235049
GI For diagram(s), see printed CA Issue.
AB The title compds. [I and II; R1, R3, R5 = H, F, Cl, Br, cyano, Me, Et, MeO, EtO, CF3; R2, R4, R6 = H, F, Cl, Br, cyano, NO2, CF3, nonafluorobutyl, R7, OR7, SR7, SO2R7, COR7, (CH2)mCO2R7, NHCOR7, NHCO2R7, p-R7C6H4, 4-R7-substituted-cyclohex-1-yl, ORs, provided that both R2 and R4 do not take the same group; R7 = C1-12 alkyl optionally interrupted by 1-3 O or substituted by cyclohexyl, cyclohexyloxy, Ph, or PhO; R8 = C2-9 alkyl having .gtoreq.3 H's substituted with F; m = 0, 1, 2] having light-, heat-, and chem. stability and good compatibility with synthetic resins, org. solvents, and liq. crystals and useful for near-IR filters, optical disk memory devices using laser beams, and liq. crystal devices for heat-mode recording by laser beam, were prepd. Thus, a mixt. of o-H2NC6H4SH 125, 1,8-dihydroxy-2,7-dibromo-4-(p-n-butylanilino)-5-(p-methylamino)anthraquinone 65, and N-methylpyrrolidone 300 parts was heated 6 h at 195-200.degree. and cooled to 70.degree.. MeOH 500 parts was added and pptd. crystals were removed by filtration, washed with MeOH and H2O, and dried to give 36 parts II (R1 = R3 = R5 = R6 = H, R2 = Me, R4 = Bu) which had .lambda.max 780 nm and .epsilon. 29 and 900.

IT 123658-61-7
RL: USES (Uses)
(prepn. of isomeric mixts. contg., as colorants for near-IR filters, optical disk memory devices, and liq. crystal devices)

RN 123658-61-7 CAPLUS
CN Benzeneacetic acid, 4-[[11-[(2-aminophenyl)thio]-13,14-dihydro-12-hydroxy-8,13-dioxo-7-(phenylamino)-8H-naphtho[2,3-a]phenothiazin-9-yl]amino]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 12 OF 20 CAPLUS COPYRIGHT 2003 ACS (Continued)



L4 ANSWER 13 OF 20 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1989:115292 CAPLUS
DOCUMENT NUMBER: 110:115292
TITLE: Selective thyromimetics. Cardiac-sparing thyroid hormone analogs containing 3'-arylmethyl substituents
AUTHOR(S): Leeson, Paul D.; Emmett, John C.; Shah, Virendra P.; Showell, Graham A.; Novelli, Ricardo; Prain, H. Douglas; Benson, Martin G.; Ellis, David; Pearce, Nigel J.; Underwood, Anthony H.
CORPORATE SOURCE: Smith Kline French Res. Ltd., Frythe/Welwyn, AL6 9AR, UK
SOURCE: Journal of Medicinal Chemistry (1989), 32(2), 320-36
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 110:115292
GI



AB Introduction of specific arylmethyl groups at the 3'-position of the thyroid hormone 3,3',5'-triiodo-L-thyronine (T3), and its known hormonally active derivs., gives liver-selective, cardiac-sparing thyromimetics (e.g., I, X = O, S; R = aryl group), with potential utility as plasma cholesterol lowering agents. Correlations between in vivo and in vitro receptor binding affinities show that liver/heart selectivity does not depend on receptor recognition but on penetration or access to receptors in vivo. QSAR studies of the binding data of a series of 20 3'-arylmethyl T3 analogs show that electroneg. groups at the para position increase both receptor binding and selectivity in vivo. However, increasing 3'-arylmethyl hydrophobicity increases receptor binding but reduces selectivity. Substitution at ortho and meta positions reduces both binding and selectivity. Replacement of the 3,5-iodo groups by halogen or Me maintains selectivity, with 3,5-dibromo analogs in particular having increased potency combined with oral bioavailability. Di-Ph thioether derivs. also have improved potency but are less orally active. At the 1-position, the D enantiomer retains selectivity, but removal of the .alpha.-amino to give a propionic acid results in loss of selective thyromimetic activity.

IT 105170-33-0P 117896-25-0P 117896-26-1P 117896-27-2P 117896-28-3P 117896-29-4P 117917-22-3P 117917-23-4P 117917-24-5P 117917-26-7P

L4 ANSWER 13 OF 20 CAPLUS COPYRIGHT 2003 ACS (Continued)
RN 117896-27-2 CAPLUS
CN L-Tyrosine, 3,5-diiodo-O-[4-methoxy-3-[(4-methoxy-3-(1-methylethyl)phenyl]methyl]phenyl]-N-(trifluoroacetyl)-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 117896-28-3 CAPLUS
CN L-Tyrosine, 3,5-diiodo-O-[4-methoxy-3-[(2-methoxyphenyl)methyl]phenyl]-N-(trifluoroacetyl)-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 117896-29-4 CAPLUS
CN L-Tyrosine, O-[3-[(3-chloro-4-methoxyphenyl)methyl]-4-methoxyphenyl]-3,5-diiodo-N-(trifluoroacetyl)-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 117917-22-3 CAPLUS
CN L-Tyrosine, O-[3-[(4-cyanophenyl)methyl]-4-methoxyphenyl]-3,5-diiodo-N-(trifluoroacetyl)-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 13 OF 20 CAPLUS COPYRIGHT 2003 ACS (Continued)
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and demethylation and hydrolysis of)
RN 105170-33-0 CAPLUS
CN L-Tyrosine, 3,5-diiodo-O-[4-methoxy-3-[(4-methoxyphenyl)methyl]phenyl]-N-(trifluoroacetyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 117896-25-0 CAPLUS
CN L-Tyrosine, O-[3-[(3-fluoro-4-methoxyphenyl)methyl]-4-methoxyphenyl]-3,5-diiodo-N-(trifluoroacetyl)-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 117896-26-1 CAPLUS
CN L-Tyrosine, 3,5-diiodo-O-[4-methoxy-3-[(4-methoxy-3-methylphenyl)methyl]phenyl]-N-(trifluoroacetyl)-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 13 OF 20 CAPLUS COPYRIGHT 2003 ACS (Continued)

Absolute stereochemistry.



RN 117917-23-4 CAPLUS
CN L-Tyrosine, 3,5-diiodo-O-[4-methoxy-3-[(4-nitrophenyl)methyl]phenyl]-N-(trifluoroacetyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 117917-24-5 CAPLUS
CN L-Tyrosine, O-[3-[(4-fluorophenyl)methyl]-4-methoxyphenyl]-3,5-diiodo-N-(trifluoroacetyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 117917-26-7 CAPLUS
CN L-Tyrosine, O-[3-[[4-(acetylamino)phenyl]methyl]-4-methoxyphenyl]-3,5-diiodo-N-(trifluoroacetyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 13 OF 20 CAPLUS COPYRIGHT 2003 ACS (Continued)



IT 105170-31-8P 117653-10-8P 117653-11-9P
117653-12-0P 117653-13-1P 117653-14-2P
117653-15-3P 117653-16-4P 117653-17-5P
117653-18-6P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. and thyromimetic activity of)
RN 105170-31-8 CAPLUS
CN L-Tyrosine, O-[4-hydroxy-3-[(4-hydroxyphenyl)methyl]phenyl]-3,5-diiodo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 117653-10-8 CAPLUS
CN L-Tyrosine, O-[3-[(4-cyanophenyl)methyl]-4-hydroxyphenyl]-3,5-diiodo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 117653-11-9 CAPLUS
CN L-Tyrosine, O-[3-[(4-fluorophenyl)methyl]-4-hydroxyphenyl]-3,5-diiodo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 13 OF 20 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 117653-15-3 CAPLUS
CN L-Tyrosine, O-[3-[(3-fluoro-4-hydroxyphenyl)methyl]-4-hydroxyphenyl]-3,5-diiodo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 117653-16-4 CAPLUS
CN L-Tyrosine, O-[3-[(3-chloro-4-hydroxyphenyl)methyl]-4-hydroxyphenyl]-3,5-diiodo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 117653-17-5 CAPLUS
CN L-Tyrosine, O-[4-hydroxy-3-[(4-hydroxy-3-methylphenyl)methyl]phenyl]-3,5-diiodo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 13 OF 20 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 117653-12-0 CAPLUS
CN L-Tyrosine, O-[4-hydroxy-3-[(4-nitrophenyl)methyl]phenyl]-3,5-diiodo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 117653-13-1 CAPLUS
CN L-Tyrosine, O-[3-[(4-aminophenyl)methyl]-4-hydroxyphenyl]-3,5-diiodo-, dihydrobromide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HBr

RN 117653-14-2 CAPLUS
CN L-Tyrosine, O-[4-hydroxy-3-[(2-hydroxyphenyl)methyl]phenyl]-3,5-diiodo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 13 OF 20 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 117653-18-6 CAPLUS
CN L-Tyrosine, O-[4-hydroxy-3-[[4-hydroxy-3-(1-methylethyl)phenyl]methyl]phenyl]-3,5-diiodo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 72469-00-2
RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)
(thyromimetic activity of)
RN 72469-00-2 CAPLUS
CN L-Tyrosine, O-[4-hydroxy-3-(phenylmethyl)phenyl]-3,5-diiodo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1988:167902 CAPLUS
DOCUMENT NUMBER: 108:167902
TITLE: Synthesis of diphenyl thioether derivatives of peptides and amino acids
AUTHOR(S): Hobbs, Doug W.; Still, W. Clark
CORPORATE SOURCE: Dep. Chem., Columbia Univ., New York, NY, 10027, USA
SOURCE: Tetrahedron Letters (1987), 28(25), 2805-8
CODEN: TELEAY; ISSN: 0040-4039
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 108:167902
GI



I

II



III

AB The photochem. SRN1 coupling of p-mercaptophenylalanine derivs. with iodotyrosine or iodophenylglycine derivs. gave di-Ph thioethers. Thus, the irradn. of iodotyrosine I and mercaptophenylalanine II with a sunlamp for 1 h in liq. NH3 gave thioether III.

IT **113850-79-6P 113850-86-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 113850-79-6 CAPLUS
CN L-Tyrosine, N-[(1,1-dimethylethoxy)carbonyl]-3,5-bis[[4-[2-[[(1,1-dimethylethoxy)carbonyl]amino]-3-methoxy-3-oxopropyl]phenyl]thio]-O-methyl-, methyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 113850-86-5 CAPLUS
CN L-Phenylalanine, 4,4'-[[5-(1-amino-2-methoxy-2-oxoethyl)-2-methoxy-1,3-phenylene]bis(thio)]bis[N-[(1,1-dimethylethoxy)carbonyl]-, dimethyl ester, (R)- (9CI) (CA INDEX NAME)



L4 ANSWER 15 OF 20 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1988:38334 CAPLUS
DOCUMENT NUMBER: 108:38334
TITLE: Thyroid hormone analogs. Synthesis of 3'-subatituted 3,5-diiodo-L-thyronines and quantitative structure-activity studies of in vitro and in vivo thyromimetic activities in rat liver and heart
AUTHOR(S): Leeson, Paul D.; Ellis, David; Emmett, John C.; Shah, Virendra P.; Showell, Graham A.; Underwood, Anthony H.
CORPORATE SOURCE: Smith Kline French Res. Ltd., Frythe/Welwyn, AL6 9AR, UK
SOURCE: Journal of Medicinal Chemistry (1988), 31(1), 37-54
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 108:38334
GI



I

AB Twenty-nine title compds. I (R = CH2:CH2, allyl, Bu, CH2CH2Ph, CH2OH, etc.) were prepd. by using established methods and by a new route involving manipulation of a 3'-formyl intermediate. In vitro hormone receptor binding (to intact nuclei) and in vivo thyromimetic activity (induction of mitochondrial 3-phosphoglycerate oxidoreductase, GPDH) were measured in rat liver and heart for these new analogs and for the 18 previously reported 3'-substituted 3,5-diiodo-L-thyronines. Anal. of the binding date using theor. conformation and quant. structure-affinity methods implies that the 3'-substituent recognition site on the thyroid hormone receptor is hydrophobic and limited in depth to the length of the natural iodo substituent, but has sufficient width to accommodate a Ph or cyclohexyl group. Receptor binding is reduced by approx. 10-fold in 3'-acyl derivs. which form strong intramol. acceptor hydrogen bonds with the adjacent 4'-hydroxyl. The compds. showed no differences in their relative affinities for heart and liver nuclei, suggesting that receptors in these tissues are similar. However, the relationships between thyromimetic activity (induction of GPDH) and nuclear binding showed some tissue differences. A high correlation between activity and binding is obsd. for full agonists in the heart, but an equally significant correlation for the liver data is only seen when 3'-substituent bulk (molar refractivity) is included in the anal. These results suggest the possibility that differential tissue penetration or access to receptors may occur in vivo.

IT **111088-02-9P 111088-36-9P 111088-50-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and deblocking of)

RN 111088-02-9 CAPLUS
CN L-Tyrosine, N-acetyl-3,5-diiodo-O-[4-methoxy-3-(phenylmethyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 20 CAPLUS COPYRIGHT 2003 ACS (Continued)

Absolute stereochemistry.



RN 111088-36-9 CAPLUS
CN L-Tyrosine, N-acetyl-O-(3-benzoyl-4-methoxyphenyl)-3,5-diiodo-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 111088-50-7 CAPLUS
CN L-Tyrosine, 3,5-diiodo-O-[4-methoxy-3-(2-phenylethyl)phenyl]-N-(trifluoroacetyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **111087-79-7P 111088-00-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and thyromimetic activity of)

RN 111087-79-7 CAPLUS
CN L-Tyrosine, O-[4-hydroxy-3-(2-phenylethyl)phenyl]-3,5-diiodo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 15 OF 20 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 111088-00-7 CAPLUS
CN L-Tyrosine, O-(3-benzoyl-4-hydroxyphenyl)-3,5-diiodo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 72469-00-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(thyromimetic activity of)
RN 72469-00-2 CAPLUS
CN L-Tyrosine, O-[4-hydroxy-3-(phenylmethyl)phenyl]-3,5-diiodo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2003 ACS (Continued)
9,10-dihydro-1,5-dihydroxy-9,10-dioxo-2,6-anthracenediyl]bis(oxy)]bis-, dibutyl ester (9CI) (CA INDEX NAME)



RN 108578-25-2 CAPLUS
CN Benzenepropanoic acid,
4,4'-[[4-[[4-(heptyloxy)phenyl]amino]-9,10-dihydro-
1,5-dihydroxy-9,10-dioxo-2,6-anthracenediyl]bis(oxy)]bis-, dibutyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



L4 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1987:215497 CAPLUS
DOCUMENT NUMBER: 106:215497
TITLE: Preparation of anthraquinone derivatives as dyes for liquid crystals
INVENTOR(S): Morishita, Yasuyoshi; Matsunaga, Daisaku; Oiso, Shoji
PATENT ASSIGNEE(S): Nippon Kayaku Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 12 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 62005941	A2	19870112	JP 1985-291950	19851226
JP 05058621	B4	19930827		
PRIORITY APPLN. INFO.:			JP 1985-50268	19850315

GI



AB The title compds. I [when X = H or NH2, Y = OH, R1 = H, R2 = Cl, Br, Q; when X = OH, Y = H or NH2, R1 = Cl, Br, Q, R2= H; Z = O, S; R3, R6 = H, F, Cl, Br, Me, Et, cyano, MeO, EtO; R4, R7 = H, F, Cl, Br, cyano, CF3, CF3(CF2)3, (substituted) alkyl, (substituted) alkoxy, acyl, acylamino, etc.; R5 = Q], useful as liq. crystal compns. such as dyes for a guest-host effect liq. crystal display device, are prepd. Heating p-BuC6H4OH 15.8, N-methylpyrrolidone 30, and K2CO3 3 parts at 150.degree., adding 11.2 parts I (R1 = R5 = Br; R2 = R3 = H; R4 = Bu; X = OH; Y = NH2) and heating at 160.degree. gave 4.2 parts I (R1 = R5 = Q where R6 = H, R7 = Bu; Z = O, R2 = R3 = H; R4 = Bu; X = OH; Y = NH2) (II), whose acetone soln. was blue. The dichroic ratios and solubilities (at 20.degree.) of 11% II with ZLI-1565 (Merck), E-8 (BDH) and ZLI-1840 (Merck) were 10.5 and 5.4%, 10.9 and 5.8%, and 11.2 and 5.0%, resp.
IT 108577-94-2P 108578-25-2P 108578-39-8P
108578-55-8P
RL: IMF (Industrial manufacture); PREP (Preparation)
(prepn. of, as dye for liq. crystal display elements)
RN 108577-94-2 CAPLUS
CN Benzeneacetic acid, 4,4'-[[4-amino-8-[[4-(ethoxycarbonyl)phenyl]amino]-

L4 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-B



RN 108578-39-8 CAPLUS
CN Benzenebutanoic acid, 4,4'-[[4-amino-5-[(4-dodecylphenyl)amino]-9,10-dihydro-1,8-dihydroxy-9,10-dioxo-2,7-anthracenediyl]bis(oxy)]bis-, dipropyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



L4 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-B

—OPr-n

RN 108578-55-8 CAPLUS
CN Benzenebutanoic acid, 4,4'-[[4-[(4-(heptyloxy)phenyl]amino]-9,10-dihydro-1,8-dihydroxy-9,10-dioxo-2,7-anthracenediyl]bis(oxy)]bis-, dioctyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



L4 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-B



L4 ANSWER 17 OF 20 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1987:131516 CAPLUS
DOCUMENT NUMBER: 106:131516
TITLE: A thyromimetic that decreases plasma cholesterol levels without increasing cardiac activity
AUTHOR(S): Underwood, A. H.; Emmett, J. C.; Ellis, D.; Flynn, S. B.; Leeson, P. D.; Benson, G. M.; Novelli, R.; Pearce, N. J.; Shah, V. P.
CORPORATE SOURCE: Smith Kline and French Res. Ltd., Welwyn/Hertfordshire, AL6 9AR, UK
SOURCE: Nature (London, United Kingdom) (1986), 324(6096), 425-9
CODEN: NATUAS; ISSN: 0028-0836
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB A new class of thyromimetics (agents that mimic the ability of the thyroid hormone T3 [6893-02-3] to decrease plasma cholesterol levels) is described. The most potent of these SKF L94901 (I) [105211-23-2] (as detd. by the induction of mitochondrial cytochrome c 3-phosphoglycerate oxidoreductase, [9001-49-4] in heart and liver of hypothyroid rats) was as active as T3 at reducing cholesterol levels and at stimulating liver function but had .apprx.0.1% the activity of T3 on heart function. In hypothyroid rats and rats with normal thyroid function, I was also shown to be a potent hypocholesterolemic agent with only a small effect on metabolic rate (detd. by whole body O consumption). The affinities of the thyromimetics for the thyroid hormone receptor of isolated heart and liver nuclei were detd., and the relationship between receptor affinity and structure is discussed.

IT 72469-00-2 105170-31-8
RL: BIOL (Biological study)
(as thyromimetic, hypocholesterolemic activity of and heart and liver functions response to, thyroid hormone receptor binding in relation to)

RN 72469-00-2 CAPLUS
CN L-Tyrosine, O-[4-hydroxy-3-(phenylmethyl)phenyl]-3,5-diiodo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 17 OF 20 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 105170-31-8 CAPLUS
CN L-Tyrosine, O-[4-hydroxy-3-[(4-hydroxyphenyl)methyl]phenyl]-3,5-diiodo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 18 OF 20 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1986:609386 CAPLUS
DOCUMENT NUMBER: 105:209386
TITLE: Thyronines and thyronine analogs
INVENTOR(S): Leeson, Paul David; Emmett, John Colin; Underwood, Anthony Hubert; Ellis, David
PATENT ASSIGNEE(S): Smith Kline and French Laboratories Ltd., UK
SOURCE: Eur. Pat. Appl., 59 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 188351	A2	19860723	EP 1986-300178	19860113
EP 188351	A3	19890315		
EP 188351	B1	19910313		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
AU 8652219	A1	19860724	AU 1986-52219	19860113
AU 577917	B2	19881006		
AT 61581	E	19910315	AT 1986-300178	19860113
CA 1319148	A1	19930615	CA 1986-499485	19860113
US 4766121	A	19880823	US 1986-818626	19860114
IL 77605	A1	19900209	IL 1986-77605	19860114
DK 8600185	A	19860719	DK 1986-185	19860115
DK 164592	B	19920720		
DK 164592	C	19921207		
ZA 8600319	A	19860827	ZA 1986-319	19860116
FI 8600229	A	19860719	FI 1986-229	19860117
NO 8600159	A	19860721	NO 1986-159	19860117
HU 40401	A2	19861228	HU 1986-244	19860117
HU 194807	B	19880328		
ES 551005	A1	19871101	ES 1986-551005	19860117
JP 61167643	A2	19860729	JP 1986-8800	19860118
JP 07103070	B4	19951108		
CN 86100894	A	19860903	CN 1986-100894	19860118
CN 1010310	B	19901107		
US 4826876	A	19890502	US 1987-136240	19871221
US 4910305	A	19900320	US 1988-168780	19880316
US 5061798	A	19911029	US 1989-428264	19891027

PRIORITY APPLN. INFO.: GB 1985-1372 19850118
EP 1986-300178 19860113
US 1986-818626 19860114
US 1988-168780 19880316

OTHER SOURCE(S): CASREACT 105:209386
GI

L4 ANSWER 18 OF 20 CAPLUS COPYRIGHT 2003 ACS (Continued)



I

AB Acids and derivs. I [R1 = 2-amino-2-carboxyethyl, CO2H, carbalkoxy, carbamoyl, carboxy-, carbalkoxy-, or carbamoylalkyl, etc.; R2 and R3 = H, halo, alkyl, NO2, NH2; Z1 = O, S, CH2; R4 = OH, alkoxy, OCH2Ph, etc.; R5 = H, alkyl; R6 = 4-HOC6H4, 5-hydroxy-2-pyridyl, 6-oxo-3(1H)-pyridyl, 6-oxo-3(1H)-pyridazinyl] were prepd., and they exhibited anticholesteremic activity in rats. A 3,5-dibromotyrosine deriv. was etherified by a diarylliodonium perchlorate deriv. to give, after deprotection, I [R1 = CH2CH(NH2)CO2H, R2 = R3 = Br, Z1 = O, R4 = HO, R5 = H, R6 = 6-oxo-3(1H)-pyridyl].

IT **105170-33-0P 105170-41-0P 105170-46-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and deprotection of)

RN 105170-33-0 CAPLUS
CN L-Tyrosine, 3,5-diiodo-O-[4-methoxy-3-[(4-methoxyphenyl)methyl]phenyl]-N-(trifluoroacetyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 105170-41-0 CAPLUS
CN L-Phenylalanine, 3,5-diiodo-4-[[4-methoxy-3-[(4-methoxyphenyl)methyl]phenyl]thio]-N-(trifluoroacetyl)-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 18 OF 20 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 105170-46-5 CAPLUS
CN L-Tyrosine, O-[4-hydroxy-3-[1-(4-hydroxyphenyl)ethyl]phenyl]-3,5-diiodo-N-(trifluoroacetyl)-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **105170-31-8P 105170-36-3P 105170-42-1P 105170-47-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as anticholesteremic)

RN 105170-31-8 CAPLUS
CN L-Tyrosine, O-[4-hydroxy-3-[(4-hydroxyphenyl)methyl]phenyl]-3,5-diiodo-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 105170-36-3 CAPLUS
CN L-Phenylalanine, 4-[[4-hydroxy-3-[(4-hydroxyphenyl)methyl]phenyl]thio]-3,5-diiodo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 18 OF 20 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 105170-42-1 CAPLUS
CN L-Tyrosine, O-[4-hydroxy-3-[1-(4-hydroxyphenyl)ethyl]phenyl]-3,5-diiodo-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 105170-47-6 CAPLUS
CN L-Tyrosine, N-acetyl-O-[4-hydroxy-3-[(4-hydroxyphenyl)methyl]phenyl]-3,5-diiodo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 19 OF 20 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1982:466791 CAPLUS
DOCUMENT NUMBER: 97:66791
TITLE: Chemical structure-biological activity study of the thyroxine binding site of human prealbumin
AUTHOR(S): Simon, Z.; Chiriac, A.; Chiriac, Veronica
CORPORATE SOURCE: Discipl. Biofiz., Inst. Med., Timisoara, Rom.
SOURCE: Timisoara Medicala (1981), 26(3), 26-8
CODEN: TIMEBY; ISSN: 0493-3079
DOCUMENT TYPE: Journal
LANGUAGE: Romanian
GI



I

AB The T4 (I) [51-48-9] receptor of human prealbumin was studied by the MTD method (Balaban, A. T., et al., 1980) based on binding data for 27 T4 derivs. (Andrea, T. A., et al., 1980). Min. steric differences were calcd. by a variant which allowed for differentation between atoms of the 2nd, 3rd, or higher periods. The structure activity relation with MTD and an indicator variant for the presence of an NH3+ group gave the values of correlation coeff. r = 0.95 and std. deviation S = 0.71 kcal/mol. These values were in agreement with those obtained by the more complex method of G. M. Crippen (1980).

IT 72469-00-2
RL: PROC (Process)
(prealbumin binding of, in human, structure in relation to)

RN 72469-00-2 CAPLUS
CN L-Tyrosine, O-[4-hydroxy-3-(phenylmethyl)phenyl]-3,5-diiodo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 19 OF 20 CAPLUS COPYRIGHT 2003 ACS (Continued)



L4 ANSWER 20 OF 20 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1980:52416 CAPLUS
DOCUMENT NUMBER: 92:52416
TITLE: Binding of thyroid hormones and analogs to the human plasma protein prealbumin
AUTHOR(S): Andrea, Tariq A.; Cavalieri, Ralph R.; Goldfine, Ira D.; Jorgensen, Eugene C.
CORPORATE SOURCE: Sch. Pharm., Univ. California, San Francisco, CA, 94143, USA
SOURCE: Biochemistry (1980), 19(1), 55-63
CODEN: BICHAW; ISSN: 0006-2960
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I



II

AB The relative binding affinities to the human plasma protein prealbumin of the thyroid hormones, L-thyroxine (I) [51-48-9] and L-3,3',5-triiodothyronine (II) [6893-02-3], and of 37 close structural analogs were measured by equil. dialysis. Anal. of the contributions of substituents to binding showed that all 4 iodine atoms contribute favorably. Addn. of an iodine atom to an analog contribute more favorably in the outer ring than in the inner ring. Halogen substituents in the 3, 5, and 3' positions contributed more to binding than did alkyl groups with the same hydrophobic character in the same positions. This suggests a H-bonding and(or) charge transfer interaction between the halogen and the protein. An electrostatic interaction between the carboxylate ion of the hormone side chain and the ammonium ion of lysine-15 accounts for the obsd. order in affinities: tetraprop [39846-93-0] > (I and D-thyroxine [51-49-0]) > thyroxamine [3571-49-1]. I bound with higher affinity than did D-thyroxine due to an interplay of electrostatic and steric forces involving the lysine-15, leucine-17, and valine-121 residues. The relative contributions of various structural features of the hormones in binding to prealbumin, I-binding globulin, and rat liver nuclear receptor were compared. Strong similarities were obsd. in the features of the 3 and 5 positions and in the side chains in contributing binding affinity to prealbumin and to the receptor. Binding to I-binding globulin and to prealbumin was influenced favorably by the same 3' and 5' substituents. In contrast, binding to the nuclear receptor was enhanced by 3' alkyl and halogen substituents but was decreased by 5' substitution.

L4 ANSWER 20 OF 20 CAPLUS COPYRIGHT 2003 ACS (Continued)

IT 72469-00-2
RL: PROC (Process)
(prealbumin binding of, structure in relation to)

RN 72469-00-2 CAPLUS
CN L-Tyrosine, O-[4-hydroxy-3-(phenylmethyl)phenyl]-3,5-diiodo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



```
=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                   91.14     239.90

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY    SESSION
CA SUBSCRIBER PRICE                                  -13.02     -13.02

STN INTERNATIONAL LOGOFF AT 15:34:03 ON 25 JUN 2003
```

=>
Uploading 10082022.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 O,S,N,CH2,CH,CF2,SO2,NH

G2 O,S

G3 O,N

G4 C,S,N,CH,CF2,Ak

G5 H,Et,n-Pr,i-Pr,n-Bu,i-Bu,s-Bu,t-Bu,Me

G6 H,Me,Et,n-Pr,i-Pr,n-Bu,i-Bu,s-Bu,t-Bu,Ak,X

G7 H,CN,X,Cb,Ak,CH2,CH,CF2,CF3

G8 H,Ak

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 09:37:43 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 8232 TO ITERATE

12.1% PROCESSED 1000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 159205 TO 170075
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 sss full

FULL SEARCH INITIATED 09:37:53 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 164456 TO ITERATE

100.0% PROCESSED 164456 ITERATIONS 62 ANSWERS
SEARCH TIME: 00.00.06

L3 62 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	148.55	148.76

FILE 'CAPLUS' ENTERED AT 09:38:04 ON 25 JUN 2003

FILE COVERS 1907 - 25 Jun 2003 VOL 138 ISS 26
FILE LAST UPDATED: 24 Jun 2003 (20030624/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 15 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2003:173554 CAPLUS
DOCUMENT NUMBER: 138:221353
TITLE: Preparation of aryloxyphenols as thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
INVENTOR(S): Malm, Johan; Brandt, Peter; Edvinsson, Karin; Koehler, Konrad; Sanin, Andrei; Gordon, Sandra
PATENT ASSIGNEE(S): Karo Bio AB, Swed.
SOURCE: PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003018515	A2	20030306	WO 2002-EP9120	20020813

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: GB 2001-20691 A 20010824
GB 2002-7719 A 20020403
OTHER SOURCE(S): MARPAT 138:221353
GI


I


II

AB Title compds. I [R1 = carboxy, ester, .alpha.-hydroxycarboxy, etc.; R2-3 = Cl, I, Br, alkyl, haloalkyl, alkenyl, etc.; R4 = halo, alkyl, alkenyl, alkynyl, etc.; X = CH2CH2, CH2CH2CH2, CH=CH, etc.; R5 = (hetero)aryl, cycloalkyl, etc.; n = 0-2] are prepd. For instance, Me 3,5-dibromo-4-(3-isopropyl-4-methoxyphenoxy)benzoate is nitrated (PhH, HNO3), reduced (EtOH, Na2S2O4) and converted to Me 3,5-dibromo-4-(3-iodo-5-isopropyl-4-methoxyphenoxy)benzoate (MeOH, HCl, KI). This intermediate was sapond. (EtOH, KOH), demethylated (CH2Cl2, BF3.bul.SMe2) and coupled to styrene (DMF, Et3N, Me3NCH2PhCl, tris(dibenzylideneacetone)dipalladium) to give II. The compds. of the invention exhibit binding affinities to the ThR.alpha. receptor in the range of 10 to 500 nM. I are useful in the treatment of cardiac and metabolic disorders, such as cardiac arrhythmias, thyrotoxicosis, subclin. hyperthyroidism and liver diseases.

IT **500794-84-3P 500794-95-6P**, (E)-3-[3,5-Dibromo-4-[3-[2-(4-((dimethylamino)methyl)phenyl)ethenyl]-4-hydroxy-5-isopropylphenoxy]phenyl]propionic acid **500794-97-8P**, (E)-4-[2-[5-[2,6-Dibromo-4-(2-carboxyethyl)phenoxy]-2-hydroxy-3-isopropylphenyl]ethenyl]benzoic acid **500795-00-6P**, 3-[3,5-Dibromo-4-[4-hydroxy-3-isopropyl-5-(phenethyl)phenoxy)phenyl]propionic acid **500795-02-8P**, (E)-3-[3,5-Dibromo-4-[4-hydroxy-3-isopropyl-5-(2-phenylethenyl)phenoxy]phenyl]-2-hydroxypropionic acid **500795-11-9P**, 3-[3,5-Dibromo-4-[4-hydroxy-3-isopropyl-5-(phenethyl)phenoxy)phenyl]-2-hydroxypropionic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(aryloxyphenols as thyroid receptor antagonists for treatment of cardiac and metabolic disorders)

RN 500794-84-3 CAPLUS
CN Benzenepropanoic acid, 3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)-5-[(1E)-2-phenylethenyl]phenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)

Double bond geometry as shown.



RN 500794-95-6 CAPLUS
CN Benzenepropanoic acid, 3,5-dibromo-4-[3-[(1E)-2-[4-[(dimethylamino)methyl]phenyl]ethenyl]-4-hydroxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 500794-97-8 CAPLUS
CN Benzenepropanoic acid, 3,5-dibromo-4-[3-[(1E)-2-(4-carboxyphenyl)ethenyl]-4-hydroxy-5-(1-methylethyl)phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 500795-00-6 CAPLUS
CN Benzenepropanoic acid, 3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)-5-(2-phenylethyl)phenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 500795-02-8 CAPLUS
CN Benzenepropanoic acid, 3,5-dibromo-.alpha.-hydroxy-4-[4-hydroxy-3-(1-methylethyl)-5-[(1E)-2-phenylethenyl]phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 500795-11-9 CAPLUS
CN Benzenepropanoic acid, 3,5-dibromo-.alpha.-hydroxy-4-[4-hydroxy-3-(1-methylethyl)-5-(2-phenylethyl)phenoxy]- (9CI) (CA INDEX NAME)



IT **500795-01-7P**, Methyl (E)-3-[3,5-dibromo-4-[4-hydroxy-3-isopropyl-5-(2-phenylethenyl)phenoxy]phenyl]propionate **500795-08-4P**, Methyl (E)-3-[3,5-dibromo-4-[4-hydroxy-3-isopropyl-5-(2-phenylethenyl)phenoxy]phenyl]-2-hydroxypropionate **500795-12-0P**, Methyl 3-[3,5-dibromo-4-(4-hydroxy-3-isopropyl-5-(phenethyl)phenoxy)phenyl]-2-hydroxypropionate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(aryloxyphenols as thyroid receptor antagonists for treatment of cardiac and metabolic disorders)

RN 500795-01-7 CAPLUS
CN Benzenepropanoic acid, 3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)-5-[(1E)-2-phenylethenyl]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L4 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 500795-08-4 CAPLUS
CN Benzenepropanoic acid, 3,5-dibromo-.alpha.-hydroxy-4-[4-hydroxy-3-(1-methylethyl)-5-[(1E)-2-phenylethenyl]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 500795-12-0 CAPLUS
CN Benzenepropanoic acid, 3,5-dibromo-.alpha.-hydroxy-4-[4-hydroxy-3-(1-methylethyl)-5-(2-phenylethyl)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)

L4 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:721656 CAPLUS
DOCUMENT NUMBER: 138:280956
TITLE: A thyroid hormone antagonist that inhibits thyroid hormone action in vivo
AUTHOR(S): Lim, Wayland; Nguyen, Ngoc-Ha; Yang, Ha Yung; Scanlan, Thomas S.; Furlow, J. David
CORPORATE SOURCE: Sect. Neurobiol., Physiol, Behavior, University of California, Davis, CA, 95616-8519, USA
SOURCE: Journal of Biological Chemistry (2002), 277(38), 35664-35670
CODEN: JBCHA3; ISSN: 0021-9258
PUBLISHER: American Society for Biochemistry and Molecular Biology
DOCUMENT TYPE: Journal
LANGUAGE: English

AB We have characterized the newly developed thyroid hormone antagonist NH-3 in both cell culture and in vivo model systems. NH-3 binds Xenopus laevis thyroid hormone receptors directly in vitro and induces a conformation distinct from agonist-bound receptors. Transcriptional activation of a thyroid hormone response element-contg. reporter gene is strongly inhibited by NH-3 in a dose-dependent manner. In addn., NH-3 prevents X. laevis thyroid hormone receptors from binding to the p160 family of co-activators GRIP-1 and SRC-1 in a two-hybrid assay. To assess the potency of the compd. in vivo, we used induced and spontaneous X. laevis tadpole metamorphosis, a thyroid hormone-dependent developmental process. NH-3 inhibits thyroid hormone-induced morphol. changes in a dose-dependent manner and inhibits the up-regulation of endogenous thyroid hormone-responsive genes. Spontaneous metamorphosis is efficiently and reversibly arrested by NH-3 with at least the same effectiveness as the thyroid hormone synthesis inhibitor methimazole. Therefore, NH-3 is the first thyroid hormone antagonist to demonstrate potent inhibition of thyroid hormone action in both cell culture- and whole animal-based assays.

IT 447415-26-1
RL: BSU (Biological study, unclassified); DMA (Drug mechanism of action); PAC (Pharmacological activity); BIOL (Biological study)
(thyroid hormone antagonist that inhibits thyroid hormone action in vivo)

RN 447415-26-1 CAPLUS
CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)-5-[(4-nitrophenyl)ethynyl]phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:716241 CAPLUS
DOCUMENT NUMBER: 137:232450
TITLE: Preparation of biphenyl derivatives as thyroid hormone analogs
INVENTOR(S): Haning, Helmut; Woltering, Michael; Schmidt, Gunter; Faeste, Christiane; Bischoff, Hilmar; Kretschmer, Axel; Voehringer, Verena; Ellinghaus, Peter
PATENT ASSIGNEE(S): Bayer Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 95 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002072539	A1	20020919	WO 2002-EP2065	20020227
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10130835	A1	20020919	DE 2001-10130835	20010627
US 2003105078	A1	20030605	US 2002-82022	20020226

PRIORITY APPLN. INFO.: DE 2001-10111651 A 20010312
DE 2001-10130835 A 20010627
OTHER SOURCE(S): MARPAT 137:232450
GI



I

AB Title compds. [I; X = O, S, SO2, CH2, CHF, CF2, NR8; R8 = H, alkyl; R1, R2 = H, alkyl; R3, R4 = H, halo, cyano, alkyl, CF3, CHF2, CH2F, vinyl, cycloalkyl; R5 = H, alkyl, halo; R6 = SR9, S(O)nR10, NR11C(O)R12, CH2, etc.; R9 = alkyl, cycloalkyl, alkenyl, aryl, arylmethyl, etc.; n = 1, 2; R10 = OR15, NR16R17, alkyl, cycloalkyl, etc.; R15 = H, Ph, benzyl, alkyl, etc.; R16, R17 = H, (branched) (substituted) alkyl, etc; R11 = H, (branched) (substituted) alkyl, etc.; R12 = (branched) (substituted) alkyl, etc.; R7 = H, alkyl, alkanoyl; Z = YmWCOR36; Y = O, S; m = 0, 1; W = (substituted) alkylene; R36 = OR37, NR38R39; R37-R39 = H, Ph, benzyl, alkyl, etc.], were prepd. as thyroid hormone analogs (no data). Thus, Et [4-(4-[benzyloxy]-3-[(4-fluorophenyl)sulfonyl]benzyl)-3,5-dimethylphenoxy]acetate (prepn. given) in EtOH was hydrogenated in the

Own work

L4 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)
presence of Pd/activated C for 2 h at room temp. and 1013 mbar to give 86% Et [4-(3-[(4-fluorophenyl)sulfonyl]-4-hydroxybenzyl)-3,5-dimethylphenoxy]acetate which was sapond. with 1 N NaOH in EtOH to give 90% [4-(3-[(4-fluorophenyl)sulfonyl]-4-hydroxybenzyl)-3,5-dimethylphenoxy]acetic acid. The compds. I are esp. suitable for use in any indications that may be treated with natural thyroid hormones such as depression or thyroid tumor. The inventive compds. I are preferably used to treat arteriosclerosis, hypercholesterolemia, dyslipidemia as well as obesity.

IT **459431-01-7P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of biphenyl derivs. as thyroid hormone analogs)

RN 459431-01-7 CAPLUS

CN Acetic acid, [4-[[3-[(4-fluorophenyl)sulfonyl]-4-hydroxyphenyl]methyl]-3,5-dimethylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



IT **459431-02-8P 459431-03-9P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of biphenyl derivs. as thyroid hormone analogs)

RN 459431-02-8 CAPLUS

CN Acetic acid, [4-[[3-[(4-fluorophenyl)sulfonyl]-4-hydroxyphenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)



RN 459431-03-9 CAPLUS

CN Propanoic acid, 2-[4-[[3-[(4-fluorophenyl)sulfonyl]-4-hydroxyphenyl]methyl]-3,5-dimethylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)



IT **459430-99-0P 459431-00-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of biphenyl derivs. as thyroid hormone analogs)

RN 459430-99-0 CAPLUS

CN Acetic acid, [4-[[3-[(4-fluorophenyl)sulfonyl]-4-(phenylmethoxy)phenyl]methyl]-3,5-dimethylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 459431-00-6 CAPLUS

CN Propanoic acid, 2-[4-[[3-[(4-fluorophenyl)sulfonyl]-4-(phenylmethoxy)phenyl]methyl]-3,5-dimethylphenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:457917 CAPLUS
DOCUMENT NUMBER: 137:169293
TITLE: Rational Design and Synthesis of a Novel Thyroid Hormone Antagonist That Blocks Coactivator Recruitment
AUTHOR(S): Nguyen, Ngoc-Ha; Apriletti, James W.; Lima, Suzana T. Cunha; Webb, Paul; Baxter, John D.; Scanlan, Thomas S.
CORPORATE SOURCE: Program in Chemistry and Chemical Biology, Departments of Pharmaceutical Chemistry and Cellular and Molecular Pharmacology, University of California, San Francisco, CA, 94143-0446, USA
SOURCE: Journal of Medicinal Chemistry (2002), 45(15), 3310-3320
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 137:169293
GI



I

II

AB The authors report the design and synthesis of a novel series of phenylethynyl derivs. I [R = H, (CH2)4Me, NO2, NH2] sharing the halogen-free thyronine scaffold of GC-1 (II). I (R = NO2) is a T3 antagonist with negligible TR agonist activity and improved TR binding affinity and potency that allow for further characterization of its obsd. activity. Its ability to block TR-coactivator interactions appears to be the mechanism for antagonism. It will be a useful pharmacol. tool for further study of T3 signaling and TR function.

IT **447415-19-2P 447415-22-7P 447415-26-1P 447415-29-4P**
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of phenylethynyl derivs. of GC-1 as thyroid hormone analogs and their binding activity towards thyroid hormone receptors)

RN 447415-19-2 CAPLUS

CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)-5-(phenylethynyl)phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 447415-22-7 CAPLUS
CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)-5-[(4-pentylphenyl)ethynyl]phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)



RN 447415-26-1 CAPLUS
CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)-5-[(4-nitrophenyl)ethynyl]phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)



RN 447415-29-4 CAPLUS
CN Acetic acid, [4-[[3-[(4-aminophenyl)ethynyl]-4-hydroxy-5-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]- (9CI) (CA INDEX NAME)



IT **446312-33-0P 446312-34-1P 446312-36-3P**

L4 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)

446312-37-4P 446312-38-5P 446312-39-6P
446312-40-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of phenylethynyl derivs. of GC-1 as thyroid hormone analogs and their binding activity towards thyroid hormone receptors)

RN 446312-33-0 CAPLUS
CN Acetic acid, [4-[[4-(methoxymethoxy)-3-(1-methylethyl)-5-(phenylethynyl)phenyl]methyl]-3,5-dimethylphenoxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 446312-34-1 CAPLUS
CN Acetic acid, [4-[[4-(methoxymethoxy)-3-(1-methylethyl)-5-[(4-pentylphenyl)ethynyl]phenyl]methyl]-3,5-dimethylphenoxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 446312-36-3 CAPLUS
CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)-5-[(4-pentylphenyl)ethynyl]phenyl]methyl]-3,5-dimethylphenoxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)

REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 446312-37-4 CAPLUS
CN Acetic acid, [4-[[3-[(4-aminophenyl)ethynyl]-4-(methoxymethoxy)-5-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 446312-38-5 CAPLUS
CN Acetic acid, [4-[[4-(methoxymethoxy)-3-(1-methylethyl)-5-[(4-nitrophenyl)ethynyl]phenyl]methyl]-3,5-dimethylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 446312-39-6 CAPLUS
CN Acetic acid, [4-[[4-hydroxy-3-(1-methylethyl)-5-[(4-nitrophenyl)ethynyl]phenyl]methyl]-3,5-dimethylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 446312-40-9 CAPLUS
CN Acetic acid, [4-[[3-[(4-aminophenyl)ethynyl]-4-hydroxy-5-(1-methylethyl)phenyl]methyl]-3,5-dimethylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2000:117013 CAPLUS
DOCUMENT NUMBER: 132:166010
TITLE: Preparation of 4-phenoxyphenylacetic acids as glucocorticoid and thyroid hormone receptor ligands for the treatment of metabolic disorders
INVENTOR(S): Apelqvist, Theresa; Goeda, Patrick; Holmgren, Erik
PATENT ASSIGNEE(S): Karo Bio AB, Swed.
SOURCE: PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000007972	A1	20000217	WO 1999-IB1447	19990804
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2339194	AA	20000217	CA 1999-2339194	19990804
AU 9951881	A1	20000228	AU 1999-51881	19990804
AU 753376	B2	20021017		
BR 9912742	A	20010502	BR 1999-12742	19990804
EP 1102739	A1	20010530	EP 1999-936913	19990804
EP 1102739	B1	20030423		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
SI 20579	C	20011231	SI 1999-20064	19990804
JP 2002522407	T2	20020723	JP 2000-563607	19990804
AT 238267	E	20030515	AT 1999-936913	19990804
BG 105214	A	20011231	BG 2001-105214	20010202
NO 2001000610	A	20010404	NO 2001-610	20010205
US 6492424	B1	20021210	US 2001-744865	20010409

PRIORITY APPLN. INFO.: GB 1998-16935 A 19980805
WO 1999-IB1447 W 19990804
OTHER SOURCE(S): MARPAT 132:166010
GI



I

L4 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)

AB The title compds. [I; R1 = alkyl, aryl, CO2H, etc.; R2, R3 = H, halo, alkyl, etc. (at least one of R2 and R3 being other than hydrogen); X = CO, CH2; R4 = alkyl, aryl, heteroaryl; R5 = halo, alkyl, cycloalkyl; Y = OH, OMe, NH2, alkylamino; n = 0-4], useful for treating diseases assocd. with metab. dysfunction or which are dependent on the expression of a glucocorticoid or thyroid receptor gene (such as diabetes, hypercholesterolemia, or obesity) (no data), were prepd. E.g., a multi-step synthesis of ester I [R1 = CO2Me; n = 1; R2 = R3 = Br; Y = OMe; R4 = Ph; X = CO; R5 = iso-Pr] was given. Compds. I are effective at 0.5-25 mg/kg/day.

IT **258819-48-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 4-phenoxyphenylacetic acids as glucocorticoid and thyroid hormone receptor ligands for the treatment of metabolic disorders)

RN 258819-48-6 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)-5-(phenylmethyl)phenoxy]- (9CI) (CA INDEX NAME)



IT **258820-36-9**
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of 4-phenoxyphenylacetic acids as glucocorticoid and thyroid hormone receptor ligands for the treatment of metabolic disorders)

RN 258820-36-9 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[4-methoxy-3-(1-methylethyl)-5-(phenylmethyl)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1996:629766 CAPLUS
DOCUMENT NUMBER: 125:261263
TITLE: Positive-working resists containing t-butoxycarbonylmethyloxybenzene dissolution inhibitor for suppressed alkaline impurity
INVENTOR(S): Watanabe, Atsushi; Ishihara, Toshinobu; Yagihashi, Fujio; Tanaka, Haruyori; Kawai, Yoshio; Nakamura, Jiro
PATENT ASSIGNEE(S): Shinetsu Chem Ind Co, Japan; Nippon Telegraph & Telephone
SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08194313	A2	19960730	JP 1995-20958	19950113

PRIORITY APPLN. INFO.: JP 1995-20958 19950113
OTHER SOURCE(S): MARPAT 125:261263
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The pos. resists comprise 3 components of an acid generator, a polymer compd., and a dissoln. inhibitor selected from 1,4-bis[bis(4-t-butoxycarbonylmethyloxyphenyl)methyl]benzene, its deriv. I (R1-2 = alkyl; k = 0-4; l = 0-2, k + l .ltoreq.4), 1,3-bis(4-t-butoxycarbonylmethyloxyphenylmethyl)-4,6-bis-t-butoxycarbonylmethyloxybenzene, its deriv. II (R = H, alkyl), bis(4-t-butoxycarbonylmethyloxy-2,5-dimethylphenyl)methyl-4-t-butoxycarbonylmethyloxybenzene, its deriv. III (R = alkyl; m = 0-4), 2,2-bis(2,4-di-t-butoxycarbonylmethyloxyphenyl)propane, its deriv. IV (R4 = alkyl; m = 0-3), 2,6-bis(2-t-butoxycarbonylmethyloxyphenylmethyl)-1-t-butoxycarbonylmethyloxy-4-methylbenzene, and its deriv. V (R = alkyl; n = 0, 1; m = 0-(4- n)). The dissoln. inhibitor suppresses penetration of an alk. impurity in the resist film and provides high-resoln. images.

IT **182216-21-3 182216-26-8 182261-28-5**
RL: TEM (Technical or engineered material use); USES (Uses)
(pos. resists contg. t-butoxycarbonylmethyloxybenzene dissoln. inhibitor for suppressed alk. impurity)

RN 182216-21-3 CAPLUS
CN Acetic acid, 2,2'-[[4,6-bis[2-(1,1-dimethylethoxy)-2-oxoethoxy]-1,3-phenylene]bis(methylene-4,1-phenyleneoxy)]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 182216-26-8 CAPLUS
CN Acetic acid, 2,2'-[[4,6-bis[2-(1,1-dimethylethoxy)-2-oxoethoxy]-5-methyl-1,3-phenylene]bis(methylene-4,1-phenyleneoxy)]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 182261-28-5 CAPLUS
CN Acetic acid, 2,2'-[[4-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-1,3-phenylene]bis[methylene(2,5-dimethyl-4,1-phenylene)oxy]]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



L4 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1996:628058 CAPLUS
DOCUMENT NUMBER: 125:261266
TITLE: 1,3-Bis(4-tert-butoxycarbonylmethyloxyphenylmethyl)-4,6-bis-tert-butoxycarbonylmethyloxybenzene derivative for dissolution inhibitor of three-component resist
INVENTOR(S): Watanabe, Atsushi; Ishihara, Toshinobu; Yagihashi, Fujio
PATENT ASSIGNEE(S): Shinetsu Chem Ind Co, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 4 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08193053	A2	19960730	JP 1995-20954	19950113
PRIORITY APPLN. INFO.:			JP 1995-20954	19950113

OTHER SOURCE(S): MARPAT 125:261266
GI



I

AB The deriv. is I (R = H, alkyl). The deriv. shows good soly. toward macromol. compd. in a three-component pos.-working resist, and is useful for dissoln. inhibitor of the resist.
IT 182216-21-3P 182216-26-8P
RL: PNU (Preparation, unclassified); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)
(prepn. of bis(carbonylmethyloxyphenylmethyl)benzene deriv. for dissoln. inhibitor of three-component resist)
RN 182216-21-3 CAPLUS
CN Acetic acid, 2,2'-[[4,6-bis[2-(1,1-dimethylethoxy)-2-oxoethoxy]-1,3-phenylene]bis(methylene-4,1-phenyleneoxy)]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

L4 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 182216-26-8 CAPLUS
CN Acetic acid, 2,2'-[[4,6-bis[2-(1,1-dimethylethoxy)-2-oxoethoxy]-5-methyl-1,3-phenylene]bis(methylene-4,1-phenyleneoxy)]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



L4 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1994:450249 CAPLUS
DOCUMENT NUMBER: 121:50249
TITLE: Computer-assisted molecular modeling of benzodiazepine and thyromimetic inhibitors of the HepG2 iodothyronine membrane transporter
AUTHOR(S): Kragie, Laura; Forrester, Maureen L.; Cody, Vivian; McCourt, Mary
CORPORATE SOURCE: Fac. Nat. Sci. Math., State Univ. New York, Buffalo, Amherst, NY, 14260, USA
SOURCE: Molecular Endocrinology (1994), 8(3), 382-91
CODEN: MOENEN; ISSN: 0888-8809
DOCUMENT TYPE: Journal
LANGUAGE: English
AB T3 cellular uptake is inhibited in the presence of benzodiazepines (BZs). The structure-activity relationship of BZ inhibition correlates strongly with halogen substitution of the nonfused Ph ring and indicates that this ring is required for activity. A structure-activity series of thyromimetic (TH) inhibitors of the HepG2 iodothyronine transporter further point out the crit. importance of the amino group of the alanine side chain, its L-stereo configuration, and the size of the substituents of the inner and outer Ph rings. A third series of compds., reported to interact at related sites, were inactive as HepG2 iodothyronine transport inhibitors, and therefore the potent inhibitors were restricted to the BZ and TH compds. Using both of these BZ and TH structure-activity series along with computer-assisted mol. modeling techniques, the authors detd. which chem. structural components were important at the transporter interaction site. By superimposing structures from active chems., excluding residues from poor inhibitors, and incorporating mol. electropotential data, the authors developed a five-point model of BZ conformational similarity to the endogenous transporter ligand, L-T3: the alkyl substitution at the N1 of the BZ ring seems to stimulate the alanine side chain of T3, and the electroneg. halogen and oxygen atoms of substituents at R3/R7/R2'/R4' of BZ form a pyrimidyl pharmacophore that seems to correspond with the 3-1/5-1/3'-1/4'-OH substituents of T3, resp. These points, suggesting a tilted cross-bow formation, may be sites for ligand interaction with the iodothyronine transporter.
IT 105170-31-8, SKF-L 93236
RL: BIOL (Biological study)
(triiodothyronine binding by iodothyronine transporter inhibition by, structure in relation to)
RN 105170-31-8 CAPLUS
CN L-Tyrosine, O-[4-hydroxy-3-[(4-hydroxyphenyl)methyl]phenyl]-3,5-diiodo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1994:435024 CAPLUS
DOCUMENT NUMBER: 121:35024
TITLE: Preparation of 4-(3-cyclohexyl-4-hydroxy or-methoxyphenylsulfonyl)-3,5-dibromophenylacetic thyromimetic cholesterol-lowering agents
INVENTOR(S): Walker, Keith A.; Labadie, Sharada S.; Kertesz, Denis J.; Laughton, Craig W.
PATENT ASSIGNEE(S): Syntex (U.S.A.) Inc., USA
SOURCE: U.S., 15 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5284971	A	19940208	US 1992-914837	19920716
PRIORITY APPLN. INFO.:			US 1992-914837	19920716

OTHER SOURCE(S): MARPAT 121:35024
GI



I

AB Title compds. I (R1 = R9CO(CHNR7R8)m(CH2)n wherein n = 1-3, m = 0,1, R7, R8 = H, C1-4 alkyl, R9 = HO, C1-4 alkoxy, R8R7N; R3, R5 = Br, Cl, iodo, Me; R31 = H, Cl, Br, iodo, C1-4 alkyl, C4-6 cycloalkyl, C1-4 haloalkyl, C4-6 halocycloalkyl, Ar(R10)CH wherein Ar = 5-hydroxypyrid-2-yl, 6-hydroxypyrid-3-yl, 6-hydroxypyridazin-3-yl, 6-methoxypyridazin-3-yl, 6-hydroxypyridazin-3-yl N-oxide, 6-methoxypyridazin-3-yl N-oxide, R10 = H, C1-4 alkyl; R41 = HO, bioprecursor) and pharmaceutically acceptable salts thereof, useful as anticholesteremic agents (no data), are prepd. SO2Cl2 in CH2Cl2 was added to Me 3,5-dibromo-4-mercaptophenylacetate (prepn. given) followed by 2-(Me2CH)C6H4OMe to give Me 3,5-dibromo-4-[(3-isopropyl-4-methoxyphenyl)thio]phenylacetate which with m-ClC6H4CO2OH in CH2Cl2 was reacted for 20 h to give I (R1 = MeO2CCH2, R3 = R5 = Br, R31 = Me2CH, R41 = MeO). Pharmaceutical formulations comprising I are given.
IT 155780-54-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as anticholesteremic)
RN 155780-54-4 CAPLUS
CN Benzeneacetic acid, 3,5-dibromo-4-[[4-hydroxy-3-[(4-hydroxyphenyl)methyl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)



L4 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1989:115292 CAPLUS
DOCUMENT NUMBER: 110:115292
TITLE: Selective thyromimetics. Cardiac-sparing thyroid hormone analogs containing 3'-arylmethyl substituents
AUTHOR(S): Leeson, Paul D.; Emmett, John C.; Shah, Virendra P.; Showell, Graham A.; Novelli, Ricardo; Prain, H. Douglas; Benson, Martin G.; Ellis, David; Pearce, Nigel J.; Underwood, Anthony H.
CORPORATE SOURCE: Smith Kline French Res. Ltd., Frythe/Welwyn, AL6 9AR, UK
SOURCE: Journal of Medicinal Chemistry (1989), 32(2), 320-36
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 110:115292
GI



I

AB Introduction of specific arylmethyl groups at the 3'-position of the thyroid hormone 3,3',5'-triiodo-L-thyronine (T3), and its known hormonally active derivs., gives liver-selective, cardiac-sparing thyromimetics (e.g., I, X = O, S; R = aryl group), with potential utility as plasma cholesterol lowering agents. Correlations between in vivo and in vitro receptor binding affinities show that liver/heart selectivity does not depend on receptor recognition but on penetration or access to receptors in vivo. QSAR studies of the binding data of a series of 20 3'-arylmethyl T3 analogs show that electroneg. groups at the para position increase both receptor binding and selectivity in vivo. However, increasing 3'-arylmethyl hydrophobicity increases receptor binding but reduces selectivity. Substitution at ortho and meta positions reduces both binding and selectivity. Replacement of the 3,5-iodo groups by halogen or Me maintains selectivity, with 3,5-dibromo analogs in particular having increased potency combined with oral bioavailability. Di-Ph thioether derivs. also have improved potency but are less orally active. At the 1-position, the D enantiomer retains selectivity, but removal of the .alpha.-amino to give a propionic acid results in loss of selective thyromimetic activity.

IT **105170-33-0P 117896-25-0P 117896-26-1P**
117896-27-2P 117896-28-3P 117896-29-4P
117917-22-3P 117917-23-4P 117917-24-5P
117917-26-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and demethylation and hydrolysis of)

RN 105170-33-0 CAPLUS

L4 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)

CN L-Tyrosine, 3,5-diiodo-O-[4-methoxy-3-[(4-methoxyphenyl)methyl]phenyl]-N-(trifluoroacetyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 117896-25-0 CAPLUS
CN L-Tyrosine, O-[3-[(3-fluoro-4-methoxyphenyl)methyl]-4-methoxyphenyl]-3,5-diiodo-N-(trifluoroacetyl)-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 117896-26-1 CAPLUS
CN L-Tyrosine, 3,5-diiodo-O-[4-methoxy-3-[(4-methoxy-3-methylphenyl)methyl]phenyl]-N-(trifluoroacetyl)-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 117896-27-2 CAPLUS
CN L-Tyrosine, 3,5-diiodo-O-[4-methoxy-3-[[4-methoxy-3-(1-methylethyl)phenyl]methyl]phenyl]-N-(trifluoroacetyl)-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 117896-28-3 CAPLUS
CN L-Tyrosine, 3,5-diiodo-O-[4-methoxy-3-[(2-methoxyphenyl)methyl]phenyl]-N-(trifluoroacetyl)-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 117896-29-4 CAPLUS
CN L-Tyrosine, O-[3-[(3-chloro-4-methoxyphenyl)methyl]-4-methoxyphenyl]-3,5-diiodo-N-(trifluoroacetyl)-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 117917-22-3 CAPLUS
CN L-Tyrosine, O-[3-[(4-cyanophenyl)methyl]-4-methoxyphenyl]-3,5-diiodo-N-(trifluoroacetyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 117917-23-4 CAPLUS
CN L-Tyrosine, 3,5-diiodo-O-[4-methoxy-3-[(4-nitrophenyl)methyl]phenyl]-N-(trifluoroacetyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 117917-24-5 CAPLUS
CN L-Tyrosine, O-[3-[(4-fluorophenyl)methyl]-4-methoxyphenyl]-3,5-diiodo-N-(trifluoroacetyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 117917-26-7 CAPLUS
CN L-Tyrosine, O-[3-[[4-(acetylamino)phenyl]methyl]-4-methoxyphenyl]-3,5-diiodo-N-(trifluoroacetyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 117653-12-0 CAPLUS
CN L-Tyrosine, O-[4-hydroxy-3-[(4-nitrophenyl)methyl]phenyl]-3,5-diiodo-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 117653-13-1 CAPLUS
CN L-Tyrosine, O-[3-[(4-aminophenyl)methyl]-4-hydroxyphenyl]-3,5-diiodo-, dihydrobromide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HBr

RN 117653-14-2 CAPLUS
CN L-Tyrosine, O-[4-hydroxy-3-[(2-hydroxyphenyl)methyl]phenyl]-3,5-diiodo-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 117653-15-3 CAPLUS

L4 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)



IT 105170-31-8P 117653-10-8P 117653-11-9P
117653-12-0P 117653-13-1P 117653-14-2P
117653-15-3P 117653-16-4P 117653-17-5P
117653-18-6P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. and thyromimetic activity of)

RN 105170-31-8 CAPLUS
CN L-Tyrosine, O-[4-hydroxy-3-[(4-hydroxyphenyl)methyl]phenyl]-3,5-diiodo-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 117653-10-8 CAPLUS
CN L-Tyrosine, O-[3-[(4-cyanophenyl)methyl]-4-hydroxyphenyl]-3,5-diiodo-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 117653-11-9 CAPLUS
CN L-Tyrosine, O-[3-[(4-fluorophenyl)methyl]-4-hydroxyphenyl]-3,5-diiodo-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN
CN L-Tyrosine, O-[3-[(3-fluoro-4-hydroxyphenyl)methyl]-4-hydroxyphenyl]-3,5-diiodo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 117653-16-4 CAPLUS
CN L-Tyrosine, O-[3-[(3-chloro-4-hydroxyphenyl)methyl]-4-hydroxyphenyl]-3,5-diiodo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 117653-17-5 CAPLUS
CN L-Tyrosine, O-[4-hydroxy-3-[(4-hydroxy-3-methylphenyl)methyl]phenyl]-3,5-diiodo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 117653-18-6 CAPLUS
CN L-Tyrosine, O-[4-hydroxy-3-[[4-hydroxy-3-(1-methylethyl)phenyl]methyl]phenyl]-3,5-diiodo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)



IT **72469-00-2**
RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)
(thyromimetic activity of)
RN 72469-00-2 CAPLUS
CN L-Tyrosine, O-[4-hydroxy-3-(phenylmethyl)phenyl]-3,5-diiodo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1988:38334 CAPLUS
DOCUMENT NUMBER: 108:38334
TITLE: Thyroid hormone analogs. Synthesis of 3'-substituted 3,5-diiodo-L-thyronines and quantitative structure-activity studies of in vitro and in vivo thyromimetic activities in rat liver and heart
AUTHOR(S): Leeson, Paul D.; Ellis, David; Emmett, John C.; Shah, Virendra P.; Showell, Graham A.; Underwood, Anthony H.
CORPORATE SOURCE: Smith Kline French Res. Ltd., Frythe/Welwyn, AL6 9AR, UK
SOURCE: Journal of Medicinal Chemistry (1988), 31(1), 37-54
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 108:38334
GI



AB Twenty-nine title compds. I (R = CH2:CH2, allyl, Bu, CH2CH2Ph, CH2OH, etc.) were prepd. by using established methods and by a new route involving manipulation of a 3'-formyl intermediate. In vitro hormone receptor binding (to intact nuclei) and in vivo thyromimetic activity (induction of mitochondrial 3-phosphoglycerate oxidoreductase, GPDH) were measured in rat liver and heart for these new analogs and for the 18 previously reported 3'-substituted 3,5-diiodo-L-thyronines. Anal. of the binding date using theor. conformation and quant. structure-affinity methods implies that the 3'-substituent recognition site on the thyroid hormone receptor is hydrophobic and limited in depth to the length of the natural iodo substituent, but has sufficient width to accommodate a Ph or cyclohexyl group. Receptor binding is reduced by approx. 10-fold in 3'-acyl derivs. which form strong intramol. acceptor hydrogen bonds with the adjacent 4'-hydroxyl. The compds. showed no differences in their relative affinities for heart and liver nuclei, suggesting that receptors in these tissues are similar. However, the relationships between thyromimetic activity (induction of GPDH) and nuclear binding showed some tissue differences. A high correlation between activity and binding is obsd. for full agonists in the heart, but an equally significant correlation for the liver data is only seen when 3'-substituent bulk (molar refractivity) is included in the anal. These results suggest the possibility that differential tissue penetration or access to receptors may occur in vivo.
IT **111088-02-9P 111088-36-9P 111088-50-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and deblocking of)
RN 111088-02-9 CAPLUS

L4 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)
CN L-Tyrosine, N-acetyl-3,5-diiodo-O-[4-methoxy-3-(phenylmethyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 111088-36-9 CAPLUS
CN L-Tyrosine, N-acetyl-O-(3-benzoyl-4-methoxyphenyl)-3,5-diiodo-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 111088-50-7 CAPLUS
CN L-Tyrosine, 3,5-diiodo-O-[4-methoxy-3-(2-phenylethyl)phenyl]-N-(trifluoroacetyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **111087-79-7P 111088-00-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and thyromimetic activity of)
RN 111087-79-7 CAPLUS
CN L-Tyrosine, O-[4-hydroxy-3-(2-phenylethyl)phenyl]-3,5-diiodo- (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)
Absolute stereochemistry.



RN 111088-00-7 CAPLUS
CN L-Tyrosine, O-(3-benzoyl-4-hydroxyphenyl)-3,5-diiodo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **72469-00-2**
RL: RCT (Reactant); RACT (Reactant or reagent)
(thyromimetic activity of)
RN 72469-00-2 CAPLUS
CN L-Tyrosine, O-[4-hydroxy-3-(phenylmethyl)phenyl]-3,5-diiodo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1987:131516 CAPLUS
DOCUMENT NUMBER: 106:131516
TITLE: A thyromimetic that decreases plasma cholesterol levels without increasing cardiac activity
AUTHOR(S): Underwood, A. H.; Emmett, J. C.; Ellis, D.; Flynn, S. B.; Leeson, P. D.; Benson, G. M.; Novelli, R.; Pearce, N. J.; Shah, V. P.
CORPORATE SOURCE: Smith Kline and French Res. Ltd., Welwyn/Hertfordshire, AL6 9AR, UK
SOURCE: Nature (London, United Kingdom) (1986), 324(6096), 425-9
CODEN: NATUAS; ISSN: 0028-0836
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB A new class of thyromimetics (agents that mimic the ability of the thyroid hormone T3 [6893-02-3] to decrease plasma cholesterol levels) is described. The most potent of these SKF L94901 (I) [105211-23-2] (as detd. by the induction of mitochondrial cytochrome c 3-phosphoglycerate oxidoreductase [9001-49-4] in heart and liver of hypothyroid rats) was as active as T3 at reducing cholesterol levels and at stimulating liver function but had .apprx.0.1% the activity of T3 on heart function. In hypothyroid rats and rats with normal thyroid function, I was also shown to be a potent hypocholesterolemic agent with only a small effect on metabolic rate (detd. by whole body O consumption). The affinities of the thyromimetics for the thyroid hormone receptor of isolated heart and liver nuclei were detd., and the relationship between receptor affinity and structure is discussed.

IT **72469-00-2 105170-31-8**
RL: BIOL (Biological study)
(as thyromimetic, hypocholesterolemic activity of and heart and liver functions response to, thyroid hormone receptor binding in relation to)

RN 72469-00-2 CAPLUS
CN L-Tyrosine, O-[4-hydroxy-3-(phenylmethyl)phenyl]-3,5-diiodo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 105170-31-8 CAPLUS
CN L-Tyrosine, O-[4-hydroxy-3-[(4-hydroxyphenyl)methyl]phenyl]-3,5-diiodo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1986:609386 CAPLUS
DOCUMENT NUMBER: 105:209386
TITLE: Thyronines and thyronine analogs
INVENTOR(S): Leeson, Paul David; Emmett, John Colin; Underwood, Anthony Hubert; Ellis, David
PATENT ASSIGNEE(S): Smith Kline and French Laboratories Ltd., UK
SOURCE: Eur. Pat. Appl., 59 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 188351	A2	19860723	EP 1986-300178	19860113
EP 188351	A3	19890315		
EP 188351	B1	19910313		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
AU 8652219	A1	19860724	AU 1986-52219	19860113
AU 577917	B2	19881006		
AT 61581	E	19910315	AT 1986-300178	19860113
CA 1319148	A1	19930615	CA 1986-499485	19860113
US 4766121	A	19880823	US 1986-818626	19860114
IL 77605	A1	19900209	IL 1986-77605	19860114
DK 8600185	A	19860719	DK 1986-185	19860115
DK 164592	B	19920720		
DK 164592	C	19921207		
ZA 8600319	A	19860827	ZA 1986-319	19860116
FI 8600229	A	19860719	FI 1986-229	19860117
NO 8600159	A	19860721	NO 1986-159	19860117
HU 40401	A2	19861228	HU 1986-244	19860117
HU 194807	B	19880328		
ES 551005	A1	19871101	ES 1986-551005	19860117
JP 61167643	A2	19860729	JP 1986-8800	19860118
JP 07103070	B4	19951108		
CN 86100894	A	19860903	CN 1986-100894	19860118
CN 1010310	B	19901107		
US 4826876	A	19890502	US 1987-136240	19871221
US 4910305	A	19900320	US 1988-168780	19880316
US 5061798	A	19911029	US 1989-428264	19891027

PRIORITY APPLN. INFO.: GB 1985-1372 19850118
EP 1986-300178 19860113
US 1986-818626 19860114
US 1988-168780 19880316

OTHER SOURCE(S): CASREACT 105:209386
GI



I

L4 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)
AB Acids and derivs. I [R1 = 2-amino-2-carboxyethyl, CO2H, carbalkoxy, carbamoyl, carboxy-, carbalkoxy-, or carbamoylalkyl, etc.; R2 and R3 = H, halo, alkyl, NO2, NH2; Z1 = O, S, CH2; R4 = OH, alkoxy, OCH2Ph, etc.; R5 = H, alkyl; R6 = 4-HOC6H4, 5-hydroxy-2-pyridyl, 6-oxo-3(1H)-pyridyl, 6-oxo-3(1H)-pyridazinyl] were prepd., and they exhibited anticholesteremic activity in rats. A 3,5-dibromotyrosine deriv. was etherified by a diaryliodonium perchlorate deriv. to give, after deprotection, I [R1 = CH2CH(NH2)CO2H, R2 = R3 = Br, Z1 = O, R4 = HO, R5 = H, R6 = 6-oxo-3(1H)-pyridyl].

IT **105170-33-0P 105170-41-0P 105170-46-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and deprotection of)

RN 105170-33-0 CAPLUS
CN L-Tyrosine, 3,5-diiodo-O-[4-methoxy-3-[(4-methoxyphenyl)methyl]phenyl]-N-(trifluoroacetyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 105170-41-0 CAPLUS
CN L-Phenylalanine, 3,5-diiodo-4-[[4-methoxy-3-[(4-methoxyphenyl)methyl]phenyl]thio]-N-(trifluoroacetyl)-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 105170-46-5 CAPLUS
CN L-Tyrosine, O-[4-hydroxy-3-[1-(4-hydroxyphenyl)ethyl]phenyl]-3,5-diiodo-N-(trifluoroacetyl)-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)



IT **105170-31-8P 105170-36-3P 105170-42-1P**
105170-47-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as anticholesteremic)

RN 105170-31-8 CAPLUS
CN L-Tyrosine, O-[4-hydroxy-3-[(4-hydroxyphenyl)methyl]phenyl]-3,5-diiodo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 105170-36-3 CAPLUS
CN L-Phenylalanine, 4-[[4-hydroxy-3-[(4-hydroxyphenyl)methyl]phenyl]thio]-3,5-diiodo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 105170-42-1 CAPLUS
CN L-Tyrosine, O-[4-hydroxy-3-[1-(4-hydroxyphenyl)ethyl]phenyl]-3,5-diiodo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 105170-47-6 CAPLUS
CN L-Tyrosine, N-acetyl-O-[4-hydroxy-3-[(4-hydroxyphenyl)methyl]phenyl]-3,5-diiodo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1982:466791 CAPLUS
DOCUMENT NUMBER: 97:66791
TITLE: Chemical structure-biological activity study of the thyroxine binding site of human prealbumin
AUTHOR(S): Simon, Z.; Chiriac, A.; Chiriac, Veronica
CORPORATE SOURCE: Discipl. Biofiz., Inst. Med., Timisoara, Rom.
SOURCE: Timisoara Medicala (1981), 26(3), 26-8
CODEN: TIMEBY; ISSN: 0493-3079
DOCUMENT TYPE: Journal
LANGUAGE: Romanian
GI



I

AB The T4 (I) [51-48-9] receptor of human prealbumin was studied by the MTD method (Balaban, A. T., et al., 1980) based on binding data for 27 T4 derivs. (Andrea, T. A., et al., 1980). Min. steric differences were calcd. by a variant which allowed for differentation between atoms of the 2nd, 3rd, or higher periods. The structure activity relation with MTD and an indicator variant for the presence of an NH3+ group gave the values of correlation coeff. r = 0.95 and std. deviation S = 0.71 kcal/mol. These values were in agreement with those obtained by the more complex method of G. M. Crippen (1980).

IT **72469-00-2**
RL: PROC (Process)
(prealbumin binding of, in human, structure in relation to)

RN 72469-00-2 CAPLUS
CN L-Tyrosine, O-[4-hydroxy-3-(phenylmethyl)phenyl]-3,5-diiodo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1980:52416 CAPLUS
DOCUMENT NUMBER: 92:52416
TITLE: Binding of thyroid hormones and analogs to the human plasma protein prealbumin
AUTHOR(S): Andrea, Tariq A.; Cavalieri, Ralph R.; Goldfine, Ira D.; Jorgensen, Eugene C.
CORPORATE SOURCE: Sch. Pharm., Univ. California, San Francisco, CA, 94143, USA
SOURCE: Biochemistry (1980), 19(1), 55-63
CODEN: BICHAW; ISSN: 0006-2960
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I



II

AB The relative binding affinities to the human plasma protein prealbumin of the thyroid hormones, L-thyroxine (I) [51-48-9] and L-3,3',5-triiodothyronine (II) [6893-02-3], and of 37 close structural analogs were measured by equil. dialysis. Anal. of the contributions of substituents to binding showed that all 4 iodine atoms contribute favorably. Addn. of an iodine atom to an analog contribute more favorably in the outer ring than in the inner ring. Halogen substituents in the 3, 5, and 3' positions contributed more to binding than did alkyl groups with the same hydrophobic character in the same positions. This suggests a H-bonding and(or) charge transfer interaction between the halogen and the protein. An electrostatic interaction between the carboxylate ion of the hormone side chain and the ammonium ion of lysine-15 accounts for the obsd. order in affinities: tetraprop [39846-93-0] > (I and D-thyroxine [51-49-0]) > thyroxamine [3571-49-1]. I bound with higher affinity than did D-thyroxine due to an interplay of electrostatic and steric forces involving the lysine-15, leucine-17, and valine-121 residues. The relative contributions of various structural features of the hormones in binding to prealbumin, I-binding globulin, and rat liver nuclear receptor were compared. Strong similarities were obsd. in the features of the 3 and 5 positions and in the side chains in contributing binding affinity to prealbumin and to the receptor. Binding to I-binding globulin and to prealbumin was influenced favorably by the same 3' and 5' substituents. In contrast, binding to the nuclear receptor was enhanced by 3' alkyl and halogen substituents but was decreased by 5' substitution.

IT **72469-00-2**
RL: PROC (Process)
(prealbumin binding of, structure in relation to)

L4 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2003 ACS (Continued)
RN 72469-00-2 CAPLUS
CN L-Tyrosine, O-(4-hydroxy-3-(phenylmethyl)phenyl)-3,5-diiodo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	68.46	217.22

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-9.77	-9.77

STN INTERNATIONAL LOGOFF AT 09:38:47 ON 25 JUN 2003